Preparation method and application of pyrrolo-ring compound as ubiquitin-specific protease 1 inhibitor and application of pyrrolo-ring compound as ubiquitin-specific protease 1 inhibitor

Nitrogen-containing heterocyclic compounds are developed as USP1 inhibitors to address the need for potent small molecule inhibitors, effectively targeting cancer by inhibiting USP1 and degrading oncogenic substrates.

CN119060071APending Publication Date: 2024-12-03JIANGXI JIMINKEXIN PHARMA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410701458.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-08-04
Filing Date
2024-05-31
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

There is a significant unmet need for potent small molecule inhibitors of ubiquitin-specific protease 1 (USP1) to target cancer and other diseases, as USP1 is often dysregulated and involved in various cellular processes related to tumor growth and survival.

Method used

Development of nitrogen-containing heterocyclic compounds represented by formula (I) and their pharmaceutically acceptable salts, which act as USP1 inhibitors, potentially inhibiting USP1 activity and degrading key proteins involved in cancer progression.

Benefits of technology

The compounds effectively inhibit USP1, offering a therapeutic approach for treating various cancer-related diseases by enhancing ubiquitination and degrading oncogenic substrates.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060071A_ABST
    Figure CN119060071A_ABST
Patent Text Reader

Abstract

The invention discloses a preparation method and application of a pyrrolo-ring compound as a ubiquitin-specific protease 1 inhibitor and application of the pyrrolo-ring compound as the ubiquitin-specific protease 1 inhibitor. Specifically, the invention discloses a compound as shown in a formula (I), an optical isomer or pharmaceutically acceptable salt of the compound, and application of the compound as a ubiquitin-specific protease 1 inhibitor. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims the priority of Chinese Patent Application No. 2023106543053 filed on June 2, 2023 and Chinese Patent Application No. 2023109788211 filed on August 4, 2023. This application cites the entire text of the above Chinese patent application. Technical Field

[0002] The present invention belongs to the field of medicinal chemistry, and in particular, relates to a preparation method, application and use of a nitrogen-containing heterocyclic compound as a ubiquitin-specific protease 1 inhibitor. Background Art

[0003] Ubiquitination is a reversible process involving a family of deubiquitinating enzymes (DUBs) that regulate various cellular processes by deconjugating ubiquitin from substrates. DUBs are encoded by approximately 100 human genes and are divided into six families, the largest of which is the ubiquitin-specific protease (USP) with more than 50 members. DUBs and their substrate proteins are often dysregulated in cancer, supporting the hypothesis that targeting specific DUB family members may lead to antitumor activity by enhancing ubiquitination and subsequently degrading the activity of other key proteins involved in tumor growth, survival, differentiation and maintenance of oncogenic substrates and tumor microenvironment. USP1 is a cysteine ​​isopeptidase of the USP subfamily of DUBs. Full-length human USP1 consists of 785 amino acids, including a catalytic triad consisting of Cys90, His593 and Asp751. USP1 deubiquitinates various cellular targets involved in different processes related to cancer. For example, USP1 deubiquitinates PCNA (proliferating cell nuclear antigen), a key protein in translesion synthesis (TLS), and FANCD2 (Fanconi anemia complementation group D2), a key protein in the Fanconi anemia (FA) pathway. Therefore, inhibition of USP1 with small molecule inhibitors has the potential to become a therapeutic approach for the treatment of cancer and other diseases. For the above reasons, there is a considerable unmet need for potent small molecule inhibitors of USP1. Summary of the invention

[0004] In one aspect of the present invention, the present invention provides a compound represented by formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof,

[0005]

[0006] in,

[0007] X1 is selected from N and CR 1X ;

[0008] X2 is selected from N and CR 2X ;

[0009] X3 Selected from NR3X ;

[0010] X4 selected from N and CR 4X ;

[0011] R1, R 1X , R 2X , R 3X , R 4X Each independently selected from H, OH, NH2, NRxR Y 、CN、F、Cl、Br、I、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl and -OC 3-6 Cycloalkyl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl or -OC 3-6 Cycloalkyl is optionally substituted with 1, 2 or 3 OH, NH2, F, Cl, Br, I, CN, NO2, COOH;

[0012] R2 is selected from phenyl, naphthyl and 5-6 membered heteroaryl, wherein the phenyl, naphthyl or 5-6 membered heteroaryl is optionally substituted with 1, 2, 3, 4 or 5 R';

[0013] R', Rx, R Y Each independently selected from H, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Heteroalkyl, -S(=O)2C 1-6 Alkyl, -OC 3-9 Cycloalkyl, -O-3-9 membered heterocyclic group, C 3-9 Cycloalkyl and 3-9 membered heterocyclic group, the C 1-6 Alkyl, C 1-6 Heteroalkyl, -S(=O)2C 1-6 Alkyl, -OC 3-9 Cycloalkyl, -O-3-9 membered heterocyclic group, C 3-9 Cycloalkyl or 3-9 membered heterocyclic group is optionally substituted by 1, 2 or 3 D, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 1-6 Alkylamino substitution;

[0014] L is selected from CR3R4, NR3, O, S, S(=O) and S(=O)2;

[0015] R3 and R4 are each independently selected from H, OH, CN, F, Cl, Br, I, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl and C 3-6 Cycloalkyl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl or C 3-6 Cycloalkyl is optionally substituted with 1, 2 or 3 OH, NH2, F, Cl, Br, I, CN, NO2, COOH;

[0016] Or, R3, R4 together with the carbon atom to which they are attached form C 3-6 Cycloalkyl, 3-9 membered heterocyclic group, C 6-14 Aryl or 5-6 membered heteroaryl, the C 3-6 Cycloalkyl, 3-9 membered heterocyclic group, C 6-14 The aryl or 5-6 membered heteroaryl is optionally substituted with 1, 2 or 3 OH, NH2, halogen, CN, C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl or -OC 3-6 Cycloalkyl substitution;

[0017] X5, X6, X7, T1, T2 are each independently selected from N and CR 5X ;

[0018] R 5X Selected from H, OH, CN, F, Cl, Br, I, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl and C 3-6 Cycloalkyl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl or C 3-6 Cycloalkyl is optionally substituted with 1, 2 or 3 OH, NH2, F, Cl, Br, I, CN, NO2, COOH;

[0019] J, K, and M are each independently selected from CR 6A R 6B NR 6A , O, S, S(=O), S(=O)(=NH) and S(=O)2;

[0020] R 6A , R 6B Each independently selected from H, OH, CN, F, Cl, Br, I, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl and C 3-6 Cycloalkyl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl or C 3-6 Cycloalkyl is optionally substituted with 1, 2 or 3 OH, NH2, F, Cl, Br, I, CN, NO2, COOH;

[0021] Ring A is selected from C 3-9 Cycloalkyl, C 6-14 Aryl, 5-9 membered heteroaryl, 3-9 membered heterocyclic group, the C 3-9 Cycloalkyl, C 6-14 Aryl, 5-9 membered heteroaryl, 3-9 membered heterocyclyl are optionally substituted by 1, 2 or 3 R5;

[0022] R5 is selected from H, D, CN, F, Cl, Br, I, -C(=O)R a 、-C(=O)OR b 、-NR a R b 、-NR a C(=O)R b 、-NR a C(=O)NR a R b 、-S(O)2NR a R b 、-C(=O)NR a R b 、-S(O)2R a 、-NR a S(O)2R b , -C 1-6 Alkyl-C(=O)NR a R b , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl, C 3-9 Cycloalkyl, OC 3-9 Cycloalkyl, C 6-14 Aryl, 5-9 membered heteroaryl, 3-9 membered heterocyclic group, -O-3-9 membered heterocyclic group, -OC 6-14Aryl and -O-5-9 membered heteroaryl, the -C(=O)R a 、-C(=O)OR b 、-NR a R b 、-NR a C(=O)R b 、-NR a C(=O)NR a R b 、-S(O)2NR a R b 、-C(=O)NR a R b 、-S(O)2R a 、-NR a S(O)2R b , -C 1-6 Alkyl-C(=O)NR a R b , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl, C 3-9 Cycloalkyl, OC 3-9 Cycloalkyl, C 6-14 Aryl, 5-9 membered heteroaryl, 3-9 membered heterocyclic group, -O-3-9 membered heterocyclic group, -OC 6-14 Aryl or -O-5-9 membered heteroaryl is optionally substituted with 1, 2 or 3 D, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 1-6 or, two optional R5 on ring A together with the carbon atom to which they are attached form C 3-6 Cycloalkyl, 3-9 membered heterocyclic group, C 6-14 Aryl or 5-6 membered heteroaryl, the C 3-6 Cycloalkyl, 3-9 membered heterocyclic group, C 6-14 The aryl or 5-6 membered heteroaryl is optionally substituted with 1, 2 or 3 OH, NH2, halogen, CN, C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl or -OC 3-6 Cycloalkyl substitution;

[0023] R a , R b Each independently selected from H, D, CN, F, Cl, Br, I, C 1-6 Alkyl, C 2-6 Alkenyl, C2-6 Alkynyl, C 1-6 Heteroalkyl, C 3-9 Cycloalkyl, OC 3-9 Cycloalkyl, C 6-14 Aryl, 5-9 membered heteroaryl, 3-9 membered heterocyclic group, -O-3-9 membered heterocyclic group, -OC 6-14 Aryl and -O-5-9 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl, C 3-9 Cycloalkyl, OC 3-9 Cycloalkyl, C 6-14 Aryl, 5-9 membered heteroaryl, 3-9 membered heterocyclic group, -O-3-9 membered heterocyclic group, -OC 6-14 Aryl and -O-5-9 membered heteroaryl are optionally substituted with 1, 2 or 3 OH, NH2, halogen, CN, C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl or -OC 3-6 Cycloalkyl substitution;

[0024] The C 1-6 The heteroalkyl, 3-9 membered heterocyclyl, 5-9 membered heterocyclyl, 5-6 membered heterocyclyl, 5-9 membered heteroaryl, 5-6 membered heteroaryl contain 1, 2, 3 or 4 heteroatoms or heteroatom groups independently selected from -O-, -NH-, -N=, -S-, -C(=O)-, -C(=O)O-, -S(=O)-, -S(=O)2- and N.

[0025] In some embodiments of the present invention, the compound represented by formula (I), its optical isomer or a pharmaceutically acceptable salt thereof, has a structure as shown below:

[0026]

[0027] in,

[0028] Y1, Y2, Y3, Y4, Y5 are each independently selected from N or C(R');

[0029] R' is independently selected from H, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Heteroalkyl, -S(=O)2C 1-6 Alkyl, -OC 3-9 Cycloalkyl, -O-3-9 membered heterocyclic group, C 3-9 Cycloalkyl and 3-9 membered heterocyclic group, the C 1-6 Alkyl, C 1-6Heteroalkyl, -S(=O)2C 1-6 Alkyl, -OC 3-9 Cycloalkyl, -O-3-9 membered heterocyclic group, C 3-9 Cycloalkyl or 3-9 membered heterocyclic group is optionally substituted by 1, 2 or 3 D, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 1-6 The remaining variables are as defined herein.

[0030] In some embodiments of the present invention, the compound represented by formula (I), its optical isomer or a pharmaceutically acceptable salt thereof, has a structure as shown below:

[0031]

[0032] in,

[0033] R 2A , R 2B , R 2C , R 2D , R 2E , R 2F , R 2G , R 2H , R 2I , R 2J , R 2K , R 2L , R 2M , R 2N , R 2O Each independently selected from H, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Heteroalkyl, -S(=O)2C 1-6 Alkyl, -OC 3-9 Cycloalkyl, -O-3-9 membered heterocyclic group, C 3-9 Cycloalkyl and 3-9 membered heterocyclic group, the C 1-6 Alkyl, C 1-6 Heteroalkyl, -S(=O)2C 1-6 Alkyl, -OC 3-9 Cycloalkyl, -O-3-9 membered heterocyclic group, C 3-9 Cycloalkyl or 3-9 membered heterocyclic group is optionally substituted by 1, 2 or 3 D, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 1-6 The remaining variables are as defined herein.

[0034] In some embodiments of the present invention, the compound represented by formula (I), its optical isomer or a pharmaceutically acceptable salt thereof, has a structure as shown below:

[0035]

[0036] in,

[0037] R 5A , R 5B , R 5C , R 5D , R 5E , R 5F , R 5G , R 5H , R 5I Each independently selected from H, D, CN, F, Cl, Br, I, -C(=O)R a 、-C(=O)OR b 、-NR a R b 、-NR a C(=O)R b 、-NR a C(=O)NR a R b 、-S(O)2NR a R b 、-C(=O)NR a R b 、-S(O)2R a 、-NR a S(O)2R b , -C 1-6 Alkyl-C(=O)NR a R b , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl, C 3-9 Cycloalkyl, OC 3-9 Cycloalkyl, C 6-14 Aryl, 5-9 membered heteroaryl, 3-9 membered heterocyclic group, -O-3-9 membered heterocyclic group, -OC 6-14 Aryl and -O-5-9 membered heteroaryl, the -C(=O)R a 、-C(=O)OR b 、-NR a R b 、-NR a C(=O)R b 、-NR a C(=O)NR a Rb 、-S(O)2NR a R b 、-C(=O)NR a R b 、-S(O)2R a 、-NR a S(O)2R b , -C 1-6 Alkyl-C(=O)NR a R b , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl, C 3-9 Cycloalkyl, OC 3-9 Cycloalkyl, C 6-14 Aryl, 5-9 membered heteroaryl, 3-9 membered heterocyclic group, -O-3-9 membered heterocyclic group, -OC 6-14 Aryl or -O-5-9 membered heteroaryl is optionally substituted with 1, 2 or 3 D, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 1-6 Alkylamino substitution;

[0038] R a , R b Each independently selected from H, D, CN, F, Cl, Br, I, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl, C 3-9 Cycloalkyl, OC 3-9 Cycloalkyl, C 6-14 Aryl, 5-9 membered heteroaryl, 3-9 membered heterocyclic group, -3-9 membered heterocyclic group, -OC 6-14 Aryl and -O-5-9 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl, C 3-9 Cycloalkyl, OC 3-9 Cycloalkyl, C 6-14 Aryl, 5-9 membered heteroaryl, 3-9 membered heterocyclic group, -O-3-9 membered heterocyclic group, -OC 6-14 Aryl and -O-5-9 membered heteroaryl are optionally substituted with 1, 2 or 3 OH, NH2, halogen, CN, C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6Cycloalkyl or -OC 3-6 The remaining variables are as defined herein.

[0039] In some embodiments of the present invention, the structural unit Selected from The remaining variables are as defined in the present invention.

[0040] In some embodiments of the present invention, the structural unit Selected from The remaining variables are as defined in the present invention.

[0041] In some embodiments of the present invention, R1, R 1X , R 2X , R 3X , R 3Y , R 4X Each independently selected from H, OH, NH2, NRxR Y 、CN、F、Cl、Br、I、C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, C 2-3 Alkenyl, C 2-3 Alkynyl, C 3-6 Cycloalkyl and -OC 3-6 Cycloalkyl, the C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, C 2-3 Alkenyl, C 2-3 Alkynyl, C 3-6 Cycloalkyl or -OC 3-6 The cycloalkyl group is optionally substituted with 1, 2 or 3 OH, NH2, F, Cl, Br, I, CN, NO2, COOH, and the remaining variables are as defined herein.

[0042] In some embodiments of the present invention, R1, R 1X , R 2X , R 3X , R 3Y , R 4X Each independently selected from H, OH, NH2, NRxR Y , CN, F, Cl, Br, I, methyl, ethyl and propyl, and the remaining variables are as defined in the present invention.

[0043] In some embodiments of the present invention, Rx, R YEach independently selected from H, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Heteroalkyl, -S(=O)2C 1-6 Alkyl, -OC 3-9 Cycloalkyl, -O-3-9 membered heterocyclic group, C 3-9 Cycloalkyl and 3-9 membered heterocyclic group, the C 1-6 Alkyl, C 1-6 Heteroalkyl, -S(=O)2C 1-6 Alkyl, -OC 3-9 Cycloalkyl, -O-3-9 membered heterocyclic group, C 3-9 Cycloalkyl or 3-9 membered heterocyclic group is optionally substituted by 1, 2 or 3 D, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 1-6 The remaining variables are as defined herein.

[0044] In some embodiments of the present invention, R2 is selected from phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrrolyl and pyrazolyl, and the phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrrolyl or pyrazolyl is optionally substituted with 1, 2, 3 or 4 R', and the remaining variables are as defined in the present invention.

[0045] In some embodiments of the present invention, R' is independently selected from H, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, -S(=O)2C 1-3 Alkyl, -OC 3-6 Cycloalkyl, -O-3-6 membered heterocyclic group, C 3-6 Cycloalkyl and 3-6 membered heterocyclic group, the C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, -S(=O)2C 1-3 Alkyl, -OC 3-6 Cycloalkyl, -O-3-6 membered heterocyclic group, C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups are optionally substituted by 1, 2 or 3 D, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio or C 1-3The remaining variables are as defined herein.

[0046] In some embodiments of the present invention, R' is independently selected from H, CN, methyl, ethyl, -OCH3, -OCH2CH3, -OCD3, -OCHF2, -SCH3, The remaining variables are as defined in the present invention.

[0047] In some embodiments of the present invention, R2 is selected from R 2A , R 2B , R 2C , R 2D , R 2E , R 2F , R 2G , R 2H , R 2I , R 2J , R 2K , R 2L , R 2M , R 2N , R 2O Selected from H, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Heteroalkyl, -S(=O)2C 1-6 Alkyl, -OC 3-9 Cycloalkyl, -O-3-9 membered heterocyclic group, C 3-9 Cycloalkyl and 3-9 membered heterocyclic group, the C 1-6 Alkyl, C 1-6 Heteroalkyl, -S(=O)2C 1-6 Alkyl, -OC 3-9 Cycloalkyl, -O-3-9 membered heterocyclic group, C 3-9 Cycloalkyl or 3-9 membered heterocyclic group is optionally substituted by 1, 2 or 3 D, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 1-6 The remaining variables are as defined herein.

[0048] In some embodiments of the present invention, R2 is selected from The remaining variables are as defined in the present invention.

[0049] In some embodiments of the present invention, R 2A , R 2B , R 2C , R2D , R 2E , R 2F , R 2G , R 2H , R 2I , R 2J , R 2K , R 2L , R 2M , R 2N , R 2O Each independently selected from H, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, -S(=O)2C 1-3 Alkyl, -OC 3-6 Cycloalkyl, -O-3-6 membered heterocyclic group, C 3-6 Cycloalkyl and 3-6 membered heterocyclic group, the C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, -S(=O)2C 1-3 Alkyl, -OC 3-6 Cycloalkyl, -O-3-6 membered heterocyclic group, C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups are optionally substituted by 1, 2 or 3 D, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio or C 1-3 The remaining variables are as defined herein.

[0050] In some embodiments of the present invention, R 2A , R 2B , R 2C , R 2D , R 2E , R 2F , R 2G , R 2H , R 2I , R 2J , R 2K , R 2L , R 2M , R 2N , R 2O Each independently selected from H, CN, methyl, ethyl, -OCH3, -OCH2CH3, -OCD3, -OCHF2, -SCH3, The remaining variables are as defined in the present invention.

[0051] In some embodiments of the present invention, L is selected from CR3R4, R3 and R4 are each independently selected from H, OH, CN, F, Cl, Br, I, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, C 2-3 Alkenyl, C 2-3 Alkynyl and C 3-6 Cycloalkyl, the C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, C 2-3 Alkenyl, C 2-3 Alkynyl or C 3-6 The cycloalkyl group is optionally substituted with 1, 2 or 3 OH, NH2, F, Cl, Br, I, CN, NO2 or COOH, and the remaining variables are as defined herein.

[0052] In some embodiments of the present invention, R3 and R4 are each independently selected from H, D, OH, CN, F, Cl, Br, I, methyl, ethyl and propyl, and the remaining variables are as defined in the present invention.

[0053] In some embodiments of the present invention, the structural unit Selected from The remaining variables are as defined in the present invention.

[0054] In some embodiments of the present invention, R 5A , R 5B , R 5C , R 5D , R 5E , R 5F , R 5G , R 5H , R 5I Each independently selected from H, D, CN, F, Cl, Br, I, C 1-6 Alkyl, C 1-6 Heteroalkyl, -OC 3-6 Cycloalkyl, -O-3-6 membered heterocyclic group, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group and -C 1-6 Alkyl-C(=O)N(C 1-6 Alkyl)2, the C 1-6 Alkyl, C 1-6 Heteroalkyl, -OC 3-6 Cycloalkyl, -O-3-6 membered heterocyclic group, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group or -C1-6 Alkyl-C(=O)N(C 1-6 The alkyl)2 is optionally substituted with 1, 2 or 3 D, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 1-6 The remaining variables are as defined herein.

[0055] In some embodiments of the present invention, R 5A , R 5B , R 5C , R 5D , R 5E , R 5F , R 5G , R 5H , R 5I Each independently selected from H, D, CN, F, Cl, Br, I, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, -OC 3-6 Cycloalkyl, -O-3-6 membered heterocyclic group, C 3-6 Cycloalkyl, 3-6 membered heteroalkyl and -C 1-3 Alkyl-C(=O)N(C 1-3 Alkyl)2, the C 1-3 Alkylthio, C 1-3 Alkylamino, -OC 3-6 Cycloalkyl, -O-3-6 membered heterocyclic group, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group or -C 1-3 Alkyl-C(=O)N(C 1-3 The alkyl)2 is optionally substituted with 1, 2 or 3 D, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 1-6 The remaining variables are as defined herein.

[0056] In some embodiments of the present invention, R 5A , R 5B , R 5C , R 5D , R 5E , R 5F , R 5G , R 5H , R 5IEach independently selected from H, D, CN, F, Cl, Br, I, OCH3, OCH2CH3, CF3, CHF2, CD3, methyl, ethyl, The remaining variables are as defined in the present invention.

[0057] In some embodiments of the present invention, Selected from The remaining variables are as defined in the present invention.

[0058] In some embodiments of the present invention, J, K, and M are each independently selected from CR 6A R 6B and O, and the remaining variables are as defined in the present invention.

[0059] In some embodiments of the present invention, R 6A , R 6B Each independently selected from H, OH, CN, F, Cl, Br, I, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, C 2-3 Alkenyl, C 2-3 Alkynyl and C 3-6 Cycloalkyl, the C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, C 2-3 Alkenyl, C 2-3 Alkynyl or C 3-6 The cycloalkyl group is optionally substituted with 1, 2 or 3 OH, NH2, F, Cl, Br, I, CN, NO2 or COOH, and the remaining variables are as defined herein.

[0060] In some embodiments of the present invention, R 6A , R 6B Each is independently selected from H, D, OH, CN, F, Cl, Br, I, methyl, ethyl and propyl, and the remaining variables are as defined herein.

[0061] In some embodiments of the present invention, the structural unit Selected from

[0062] R 5A , R 5B Each independently selected from H, D, CN, F, Cl, Br, I, C 1-6 Alkyl, C 1-6 Heteroalkyl, -OC 3-6 Cycloalkyl, -O-3-6 membered heterocyclic group, C3-6 Cycloalkyl, 3-6 membered heterocyclic group and -C 1-6 Alkyl-C(=O)N(C 1-6 Alkyl)2, the C 1-6 Alkyl, C 1-6 Heteroalkyl, -OC 3-6 Cycloalkyl, -O-3-6 membered heterocyclic group, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group or -C 1-6 Alkyl-C(=O)N(C 1-6 The alkyl)2 is optionally substituted with 1, 2 or 3 D, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 1-6 The remaining variables are as defined herein.

[0063] In some embodiments of the present invention, the structural unit Selected from The remaining variables are as defined in the present invention.

[0064] In another aspect of the present invention, the present invention also proposes a compound of the following formula, an optical isomer thereof or a pharmaceutically acceptable salt thereof, which is selected from:

[0065]

[0066]

[0067]

[0068] In another aspect of the present invention, the present invention also proposes a compound of the following formula, an optical isomer thereof or a pharmaceutically acceptable salt thereof, which is selected from:

[0069]

[0070] In another aspect of the present invention, the present invention also provides the use of the aforementioned compound, its optical isomer or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating a disease associated with USP1 activity or expression.

[0071] In some embodiments of the present invention, the above-mentioned diseases related to USP1 activity or expression level are selected from cancer-related diseases and the like.

[0072] In some embodiments of the present invention, the above-mentioned cancer-related diseases are selected from bone cancer, brain cancer, soft tissue cancer, kidney cancer, bladder cancer, skin cancer, lung cancer, colon cancer, nervous system cancer, head and neck cancer, pancreatic cancer, ovarian cancer, breast cancer, uterine cancer, cervical cancer, etc.

[0073] In some embodiments of the present invention, the above-mentioned bone cancer is selected from osteosarcoma, chondrosarcoma, etc.

[0074] In some embodiments of the present invention, the above-mentioned brain cancer is selected from glioma, glioblastoma, astrocytoma, medulloblastoma, meningioma, etc.

[0075] In some embodiments of the present invention, the above-mentioned soft tissue cancer is selected from rhabdoid sarcoma and the like.

[0076] In some embodiments of the present invention, the above-mentioned skin cancer is selected from melanoma and the like.

[0077] In some embodiments of the present invention, the above-mentioned lung cancer is selected from non-small cell lung cancer and the like.

[0078] Definition and Description

[0079] Unless otherwise specified, the following terms and phrases used herein are intended to have the following meanings. A particular term or phrase should not be considered to be uncertain or unclear in the absence of a special definition, but should be understood according to its ordinary meaning. When a trade name appears in this article, it is intended to refer to its corresponding commercial product or its active ingredient.

[0080] As in the present invention, the phrase "at least one" used when referring to a list of one or more elements should be understood to mean at least one element selected from any one or more elements in the list of elements, but does not necessarily include at least one of each element specifically listed in the list of elements, and does not exclude any combination of elements in the list of elements. This definition also allows that there may be optionally elements other than the elements specifically identified in the list of elements to which the phrase "at least one" refers, whether related or unrelated to those specifically identified elements.

[0081] The term "pharmaceutically acceptable" as used herein refers to those compounds, materials, compositions and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response or other problems or complications, commensurate with a reasonable benefit / risk ratio.

[0082] The term "pharmaceutically acceptable salt" refers to salts of compounds of the invention, prepared from compounds of the invention having specific substituents with relatively nontoxic acids or bases. When the compounds of the invention contain relatively acidic functional groups, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of base in a pure solution or a suitable inert solvent. Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amine or magnesium salts or similar salts. When the compounds of the invention contain relatively basic functional groups, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of acid in a solution or a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include inorganic acid salts, such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, hydrogen sulfate, hydroiodic acid, phosphorous acid, etc.; and organic acid salts, such as acetic acid, propionic acid, isobutyric acid, trifluoroacetic acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid, tartaric acid and methanesulfonic acid, and salts of amino acids (such as arginine, etc.), and salts of organic acids such as glucuronic acid. Certain specific compounds of the present invention contain basic and acidic functional groups, and thus can be converted into any base or acid addition salt.

[0083] Pharmaceutically acceptable salts of the present invention can be synthesized by conventional chemical methods from parent compounds containing acid radicals or bases. Generally, the preparation method of such salts is: in water or an organic solvent or a mixture of the two, these compounds in the form of free acids or bases are prepared by reacting with a stoichiometric amount of appropriate base or acid.

[0084] "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semi-solid or liquid filler, diluent, encapsulating material, formulation aid or carrier commonly used with therapeutic agents in the art, which together constitute a "pharmaceutical composition" for administration to a subject. A pharmaceutically acceptable carrier is non-toxic to the recipient at the dosage and concentration used and is compatible with the other ingredients of the formulation. The pharmaceutically acceptable carrier is suitable for the formulation used.

[0085] Since the compounds of the present disclosure are inhibitors of USP1 protein, the present disclosure provides a method for inhibiting USP1 protein, the method comprising contacting USP1 protein or a composition comprising USP1 protein with one or more compounds of the present disclosure.

[0086] Since the compounds of the present disclosure are inhibitors of USP1 proteins, a variety of diseases, disorders or conditions mediated by USP1 proteins can be treated by employing the compounds. Thus, the present disclosure generally relates to a method for treating a disease, disorder or condition in an animal suffering from or at risk of a condition responsive to inhibition of USP1 proteins, the method comprising administering to the animal an effective amount of one or more compounds of the present disclosure.

[0087] The present disclosure further relates to a method of inhibiting USP1 protein in an animal in need thereof, the method comprising administering to the animal a therapeutically effective amount of at least one compound of the present disclosure.

[0088] As used herein, "USP1" and "ubiquitin-specific protease 1" refer to any native polypeptide or polynucleotide encoding USP1. The term "USP1" encompasses "full-length" unprocessed USP1 polypeptides as well as any form of USP1 resulting from processing within the cell (e.g., removal of the signal peptide). The term also encompasses naturally occurring variants of USP1, such as those encoded by splice variants and allelic variants. The USP1 polypeptides described herein may be derived from a variety of sources, such as isolated from a human tissue type or from another source, or produced by recombinant or synthetic methods. Human USP1 sequences are known and include, for example, sequences publicly available as UniProt No. 094782 (including isoforms). As used herein, the term "human USP1 protein" refers to a USP1 protein comprising an amino acid sequence as shown in SEQ ID NO: 1 in U.S. Provisional Patent Application No. 62 / 857,986, filed on June 6, 2019.

[0089] USP1 is a deubiquitinase that acts as part of a complex with UAF1. The "deubiquitinase activity" of USP1 includes its ability to deubiquitinate as part of the USP1-UAF1 complex.

[0090] The term "specific binding" to a protein or a domain of a protein is a well-known term in the art, and methods for determining the specific binding achieved are also well-known in the art. A molecule is considered to exhibit "specific binding" or "preferential binding" if it reacts or associates with a particular protein or a domain of a protein more frequently, more quickly, for a longer period of time, and / or with a higher affinity than it reacts or associates with an alternative protein or domain. It should be understood that a molecule that specifically or preferentially binds to a first protein or domain may or may not specifically or preferentially bind to a second protein or domain. Therefore, "specific binding" or "preferential binding" does not necessarily require (but may include) exclusive binding. In general, but not necessarily, reference to binding means preferential binding. For example, a USP1 inhibitor that specifically binds to USP1, UAF1, and / or a USP1-UAF1 complex may not bind to other deubiquitinating enzymes, other USP proteins, or other UAF1 complexes (USP46-UAF1), or may bind to other deubiquitinating enzymes, other USP proteins, or other UAF1 complexes (e.g., USP46-UAF1) with lower affinity than it binds to USP1.

[0091] As used herein, the terms "cancer" and "tumor" refer to or describe a physiological condition in which a population of cells in a mammal is characterized by unregulated cell growth. The terms encompass solid cancers and blood / lymphoid cancers. Examples of cancer include, but are not limited to, cancers with defects in DNA damage repair pathways. Other examples of cancer include, but are not limited to, ovarian cancer, breast cancer (including triple-negative breast cancer), non-small cell lung cancer (NSCLC), and osteosarcoma. The cancer may be BRCA1 or BRCA2 wild type. The cancer may also be BRCA1 or BRCA2 mutant. The cancer may also be a PARP inhibitor-resistant or refractory cancer, or a PARP inhibitor-resistant or refractory BRCA1 or BRCA2 mutant cancer.

[0092] When any variable (e.g., R) occurs more than once in a compound's composition or structure, its definition in each case is independent. Thus, for example, if a group is substituted with 0-2 Rs, the group may optionally be substituted with up to two Rs, and each case of R has an independent option. For example, if a group is substituted with 1, 2, or 3 R's, the group may optionally be substituted with 1 or 2 or 3 R's, and each case of R' has an independent option. In addition, combinations of substituents and / or variants thereof are permitted only if such combinations result in stable compounds. For example, Can be selected from wait.

[0093] A hyphen ("-") not between two letters or symbols indicates the point of attachment of a substituent. 1-6 Alkylcarbonyl - refers to a C- 1-6 However, when the attachment point of the substituent is obvious to those skilled in the art, for example, a halogen substituent, the "-" may be omitted.

[0094] When the group bond is marked with a dotted line When, for example, In the examples, the dashed line represents the point of attachment of the group to the rest of the molecule.

[0095] The term "substituted" or "substituted by..." means that any one or more hydrogen atoms on a specific atom are replaced by a substituent, which may include deuterium and hydrogen variants, as long as the valence state of the specific atom is normal and the substituted compound is stable. The term "optionally substituted" or "optionally substituted by..." means that it may be substituted or not substituted, and unless otherwise specified, the type and number of the substituents may be any on the basis of chemical practicability.

[0096] When one of the variables is selected from a single bond, it means that the two groups it connects are directly connected, such as When L1 represents a single bond, it means that the structure is actually

[0097] When the substituent is listed without indicating the atom through which it is connected to the substituted group, the substituent can be bonded through any atom thereof. For example, a pyridyl substituent can be bonded to the substituted group through any carbon atom on the pyridine ring.

[0098] When the listed linking group does not indicate its linking direction, its linking direction is arbitrary, for example, The connecting group L is -CH2O-, in which case -CH2O- can connect phenyl and cyclopentyl in the same direction as the reading order from left to right to form It is also possible to connect phenyl and cyclopentyl groups in the opposite direction of reading from left to right to form Combinations of linkers, substituents, and / or variations thereof are permissible only if such combinations result in stable compounds.

[0099] The term "halogen" refers to fluorine, chlorine, bromine, iodine.

[0100] The term "deuterium" is also called heavy hydrogen or hydrogen-2. It is a stable isotope of hydrogen, and its element symbol is usually D or 2 H.

[0101] Unless otherwise specified, the number of atoms in a ring is generally defined as the ring member number, for example, "3-6 membered ring" refers to a "ring" having 3-6 atoms arranged around it.

[0102] Unless otherwise specified, the term “C 1-6 "Alkyl" is used to refer to a straight or branched chain saturated hydrocarbon group consisting of 1 to 6 carbon atoms. 1-6 Alkyl groups include C 1-5 , C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C6 and C5 alkyl, etc.; it can be monovalent (such as CH3), divalent (-CH2-) or polyvalent (such as C 1-6 Examples of alkyl groups include, but are not limited to, CH3, wait.

[0103] Unless otherwise specified, the term “C 1-4 "Alkyl" is used to refer to a straight or branched chain saturated hydrocarbon group consisting of 1 to 4 carbon atoms. 1-4 Alkyl groups include C 1-2 , C 1-3 , C 3-4 and C 2-3 Alkyl, etc.; it can be monovalent (such as CH3), divalent (-CH2-) or polyvalent (such as C 1-4 Examples of alkyl groups include, but are not limited to, CH3, wait.

[0104] Unless otherwise specified, “C 2-6 "Alkenyl" is used to refer to a straight or branched hydrocarbon group consisting of 2 to 6 carbon atoms containing at least one carbon-carbon double bond, which may be located at any position of the group. 2-6 Alkenyl includes C 2-4 , C 2-3 , C4, C3 and C2 alkenyl, etc.; which may be monovalent, divalent or polyvalent. 2-6 Examples of alkenyl groups include, but are not limited to, ethenyl, propenyl, butenyl, pentenyl, hexenyl, butadienyl, piperyl, hexadienyl, and the like.

[0105] Unless otherwise specified, “C 2-3 "Alkenyl" is used to refer to a straight or branched hydrocarbon group consisting of 2 to 3 carbon atoms containing at least one carbon-carbon double bond, which may be located at any position of the group. 2-3 Alkenyl includes C3 and C2 alkenyl; the C 2-3The alkenyl group may be monovalent, divalent or polyvalent. 2-3 Examples of alkenyl groups include, but are not limited to wait.

[0106] Unless otherwise specified, “C 2-6 "Alkynyl" is used to refer to a straight or branched hydrocarbon group consisting of 2 to 6 carbon atoms containing at least one carbon-carbon triple bond, which can be located at any position of the group. It can be monovalent, divalent or polyvalent. The C 2-6 Alkynyl groups include C 2-3 , C 2-4 , C 2-5 , C 3-4 , C 3-5 , C 3-6 , C 4-5 , C 4-6 , C 5-6 , C6, C5, C4, C3 and C2 alkynyl. 2-6 Examples of alkynyl groups include, but are not limited to wait.

[0107] Unless otherwise specified, “C 2-3 "Alkynyl" is used to refer to a straight or branched hydrocarbon group consisting of 2 to 3 carbon atoms containing at least one carbon-carbon triple bond, which can be located at any position of the group. It can be monovalent, divalent or polyvalent. The C 2-3 Alkynyl groups include C3 and C2 alkynyl groups. 2-3 Examples of alkynyl groups include, but are not limited to wait.

[0108] The term "heteroalkyl" by itself or in combination with another term refers to a stable straight or branched alkyl radical or combination thereof consisting of a certain number of carbon atoms and at least one heteroatom or heteroatom group. In some embodiments, the heteroatom is selected from B, O, N and S, wherein the nitrogen and sulfur atoms are optionally oxidized and the nitrogen heteroatom is optionally quaternized. In other embodiments, the heteroatom group is selected from -C(=O)O-, -C(=O)-, -C(=S)-, -S(=O), -S(=O)2-, -C(=O)N(H)-, -N(H)-, -C(=NH)-, -S(=O)2N(H)- and -S(=O)N(H)-. In some embodiments, the heteroalkyl is C 1-6 In other embodiments, the heteroalkyl group is C 1-3Heteroalkyl. The heteroatom or heteroatom group may be located at any interior position of the heteroalkyl group, including the position at which the alkyl group is attached to the remainder of the molecule, but the term "alkoxy" is a customary expression to refer to those alkyl groups that are attached to the remainder of the molecule through an oxygen atom. Examples of heteroalkyl groups include, but are not limited to, -OCH3, -OCH2CH3, -OCH2CH2CH3, -OCH(CH3)2, -CH2-CH2-O-CH3, -NHCH3, -N(CH3)2, -NHCH2CH3, -N(CH3)(CH2CH3), -CH2-CH2-NH-CH3, -CH2-CH2-N(CH3)-CH3, -SCH3, -SCH2CH3, -SCH2CH2CH3, -SCH(CH3)2, -CH2-S-CH2-CH3, -CH2-CH2-S-CH3, -S(=O)-CH3, -CH2-CH2-S(=O)2-CH3, and up to two heteroatoms may be consecutive, for example, -CH2-NH-OCH3.

[0109] Unless otherwise specified, the term “C 1-6 "Alkoxy" refers to those alkyl groups containing 1 to 6 carbon atoms which are attached to the rest of the molecule via an oxygen atom. 1-6 Alkoxy includes C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C6, C5, C4 and C3 alkoxy, etc. 1-6 Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), butoxy (including n-butoxy, isobutoxy, s-butoxy and t-butoxy), pentoxy (including n-pentoxy, isopentoxy and neopentoxy), hexyloxy, and the like.

[0110] Unless otherwise specified, the term “C 1-3 "Alkoxy" refers to those alkyl groups containing 1 to 3 carbon atoms which are attached to the rest of the molecule via an oxygen atom. 1-3 Alkoxy includes C 1-3 , C 1-2 , C 2-3 , C1, C2 and C3 alkoxy, etc. 1-3 Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (including n-propoxy and isopropoxy), and the like.

[0111] Unless otherwise specified, the term “C 1-6 "Alkylamino" refers to those alkyl groups containing 1 to 6 carbon atoms which are attached to the rest of the molecule through an amino group. 1-6Alkylamino groups include C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C6, C5, C4, C3 and C2 alkylamino, etc. 1-6 Examples of alkylamino groups include, but are not limited to, -NHCH3, -N(CH3)2, -NHCH2CH3, -N(CH3)CH2CH3, -N(CH2CH3)(CH2CH3), -NHCH2CH2CH3, -NHCH(CH3)2, -NHCH2CH2CH2CH3, and the like.

[0112] Unless otherwise specified, the term “C 1-3 "Alkylamino" refers to those alkyl groups containing 1 to 3 carbon atoms which are attached to the rest of the molecule through an amino group. 1-3 Alkylamino groups include C 1-3 , C 1-2 , C 2-3 , C1, C2 and C3 alkylamino, etc. 1-3 Examples of alkylamino groups include, but are not limited to, -NHCH3, -N(CH3)2, -NHCH2CH3, -N(CH3)CH2CH3, -NHCH2CH2CH3, -NHCH(CH3)2, and the like.

[0113] Unless otherwise specified, the term “C 1-6 "Alkylthio" refers to those alkyl groups containing 1 to 6 carbon atoms which are attached to the rest of the molecule via a sulfur atom. 1-6 Alkylthio includes C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-4 , C6, C5, C4, C3 and C2 alkylthio, etc. 1-6 Examples of alkylthio groups include, but are not limited to, -SCH3, -SCH2CH3, -SCH2CH2CH3, -SCH(CH3)2, and the like.

[0114] Unless otherwise specified, the term “C 1-3 "Alkylthio" refers to those alkyl groups containing 1 to 3 carbon atoms which are attached to the rest of the molecule via a sulfur atom. 1-3 Alkylthio includes C 1-3 , C 1-2 , C 2-3 , C1, C2 and C3 alkylthio, etc. 1-3 Examples of alkylthio groups include, but are not limited to, -SCH3, -SCH2CH3, -SCH2CH2CH3, -SCH(CH3)2, and the like.

[0115] Unless otherwise specified, “C 3-9 "Cycloalkyl" means a saturated cyclic hydrocarbon group consisting of 3 to 9 carbon atoms, which is a monocyclic or bicyclic system. 3-9 Cycloalkyl includes C 3-8 , C 3-7 , C 3-6 , C 3-5 and C 5-6 Cycloalkyl, etc.; it may be monovalent, divalent or polyvalent. 3-9 Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and the like.

[0116] Unless otherwise specified, “C 3-6 "Cycloalkyl" means a saturated cyclic hydrocarbon group consisting of 3 to 6 carbon atoms, which is a monocyclic or bicyclic system. 3-6 Cycloalkyl groups include C 3-5 , C 4-5 and C 5-6 Cycloalkyl, etc.; it may be monovalent, divalent or polyvalent. 3-6 Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and the like.

[0117] Unless otherwise specified, the term "3-9 membered heterocyclyl" by itself or in combination with other terms means a saturated or partially unsaturated cyclic group consisting of 3 to 9 ring atoms, 1, 2, 3 or 4 of which are heteroatoms independently selected from O, S and N, and the rest are carbon atoms, wherein the nitrogen atom is optionally quaternized, and the carbon, nitrogen and sulfur atoms are independently optionally oxidized (i.e., C=O, NO and S(O) p , p is 1 or 2). It includes monocyclic and bicyclic systems, wherein the bicyclic system includes spirocyclic, cyclic and bridged rings. In addition, with respect to the "3-9 membered heterocyclic group", heteroatoms can occupy the connection position of the heterocyclic group with the rest of the molecule. The 3-9 membered heterocyclic group includes 3-8, 3-7, 3-6, 3-5, 3-4, 4-5, 4-6, 4-7, 4-8, 4-9, 5-6, 5-7, 5-8, 5-9, 6-7, 6-8, 6-9, 7-8, 3, 4, 5, 6, 7, 8 and 9 membered heterocyclic groups. Examples of 3-9 membered heterocyclic groups include, but are not limited to, azetidinyl, oxetanyl, thietanyl, 1,3-dioxolane, Pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothiophenyl (including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.), tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2-piperidinyl and 3-piperidinyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), dioxanyl, dithianyl, isoxazolidinyl, isothiazolidinyl, 1,2-oxazinyl, 1,2-thiazinyl, hexahydropyridazinyl, homopiperazinyl or homopiperidinyl, etc.

[0118] Unless otherwise specified, the term "5-6 membered heterocyclyl" by itself or in combination with other terms means a saturated or partially unsaturated cyclic group consisting of 5 to 6 ring atoms, 1, 2, 3 or 4 of which are heteroatoms independently selected from O, S and N, and the rest are carbon atoms, wherein the nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms are optionally oxidized (i.e., NO and S(O) p , p is 1 or 2). It includes monocyclic and bicyclic systems, wherein bicyclic systems include spirocyclic, fused and bridged rings. In addition, with respect to the "5-6 membered heterocyclic group", a heteroatom may occupy the position where the heterocyclic group is connected to the rest of the molecule. The 5-6 membered heterocyclic group includes 5-membered and 6-membered heterocyclic groups, etc. Examples of 5-6 membered heterocyclic groups include, but are not limited to, 1,3-dioxolane, Pyrrolidinyl, pyrazolidinyl, imidazolidinyl, tetrahydrothiophenyl (including tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl, etc.), tetrahydrofuranyl (including tetrahydrofuran-2-yl, etc.), tetrahydropyranyl, piperidinyl (including 1-piperidinyl, 2-piperidinyl and 3-piperidinyl, etc.), piperazinyl (including 1-piperazinyl and 2-piperazinyl, etc.), morpholinyl (including 3-morpholinyl and 4-morpholinyl, etc.), dioxanyl, dithianyl, isoxazolidinyl, isothiazolidinyl, 1,2-oxazinyl, 1,2-thiazinyl, hexahydropyridazinyl, homopiperazinyl or homopiperidinyl, etc.

[0119] Unless otherwise specified, the terms "5-9 membered heteroaromatic ring" and "5-9 membered heteroaryl" are used interchangeably in the present invention. The term "5-9 membered heteroaryl" refers to a monocyclic group with a conjugated π electron system consisting of 5 to 9 ring atoms, wherein 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from O, S and N, and the rest are carbon atoms. The nitrogen atom is optionally quaternized, and the nitrogen and sulfur heteroatoms are optionally oxidized (i.e., NO and S(O) p, p is 1 or 2). The 5-9 membered heteroaryl group may be attached to the rest of the molecule via a heteroatom or a carbon atom. The 5-9 membered heteroaryl group includes 5-8 membered, 5-7 membered, 5-6 membered, 5 membered and 6 membered heteroaryl groups. Examples of the 5-9 membered heteroaryl group include, but are not limited to, pyrrolyl (including N-pyrrolyl, 2-pyrrolyl and 3-pyrrolyl, etc.), pyrazolyl (including 2-pyrazolyl and 3-pyrazolyl, etc.), imidazolyl (including N-imidazolyl, 2-imidazolyl, 4-imidazolyl and 5-imidazolyl, etc.), oxazolyl (including 2-oxazolyl, 4-oxazolyl and 5-oxazolyl, etc.), triazolyl (1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1H-1,2,4-triazolyl and 4H-1,2,4-triazolyl, etc.), tetrazolyl, isoxazolyl (3-isoxazolyl, 4-isoxazolyl and 5-isoxazolyl, etc.), thiazolyl (including 2-thiazolyl, 4-thiazolyl) oxazolyl and 5-thiazolyl, etc.), furanyl (including 2-furanyl and 3-furanyl, etc.), thienyl (including 2-thienyl and 3-thienyl, etc.), pyridyl (including 2-pyridyl, 3-pyridyl and 4-pyridyl, etc.), pyrazinyl or pyrimidinyl (including 2-pyrimidinyl and 4-pyrimidinyl, etc.), benzothiazolyl (including 5-benzothiazolyl, etc.), purinyl, benzimidazolyl (including 2-benzimidazolyl, etc.), benzoxazolyl, indolyl (including 5-indolyl, etc.), isoquinolyl (including 1-isoquinolyl and 5-isoquinolyl, etc.), quinoxalinyl (including 2-quinoxalinyl and 5-quinoxalinyl, etc.) or quinolyl (including 3-quinolyl and 6-quinolyl, etc.).

[0120] Unless otherwise specified, the term “C 6-14 "Aryl" by itself or in combination with other terms refers to a monocyclic or bicyclic aromatic ring system having six to fourteen carbon atoms, respectively. Non-limiting exemplary aryl groups include phenyl (abbreviated as "Ph"), naphthyl, phenanthrenyl, anthryl, indenyl, azulenyl, biphenyl, biphenylene and fluorenyl. The aryl group may be selected from phenyl or theanyl group. The aryl group may be phenyl.

[0121] Unless otherwise specified, C n-n+m or C n -C n+m Any specific case including n to n+m carbons, such as C 1-12 Including C1, C2, C3, C4, C5, C6, C7, C8, C9, C 10 , C 11 , and C 12 , also includes any range from n to n+m, such as C 1-12 Including C 1-3 , C 1-6 , C 1-9 , C 3-6 , C 3-9 , C 3-12 , C6-9 , C 6-12 , and C 9-12 etc.; similarly, n-membered to n+m-membered means that the number of atoms in the ring is n to n+m, for example, 3-12-membered ring includes 3-membered ring, 4-membered ring, 5-membered ring, 6-membered ring, 7-membered ring, 8-membered ring, 9-membered ring, 10-membered ring, 11-membered ring, and 12-membered ring, and also includes any range from n to n+m, for example, 3-12-membered ring includes 3-6-membered ring, 3-9-membered ring, 5-6-membered ring, 5-7-membered ring, 5-10-membered ring, 6-7-membered ring, 6-8-membered ring, 6-9-membered ring and 6-10-membered ring, etc.

[0122] Unless otherwise specified, where substituents are specified using their conventional chemical formula written from left to right, they equally encompass chemically identical substituents resulting from writing the structure from right to left, e.g., -C(=O)-O- is equivalent to -OC(=O)-.

[0123] It will be appreciated by those skilled in the art that some compounds of formula (I) may contain one or more chiral centers and therefore may exist as two or more stereoisomers. Therefore, the compounds of the present invention may exist as single stereoisomers (e.g. enantiomers, diastereomers) and mixtures thereof in any proportion, such as racemates, and, where appropriate, as tautomers and geometric isomers.

[0124] The compounds of the present invention may exist in specific geometric or stereoisomeric forms. The present invention contemplates all such compounds, including cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic mixtures and other mixtures thereof, such as enantiomerically or diastereomerically enriched mixtures, all of which are within the scope of the present invention. Additional asymmetric carbon atoms may be present in substituents such as alkyl. All of these isomers and their mixtures are included within the scope of the present invention.

[0125] The term "stereoisomer" as used herein refers to compounds that have identical chemical constitution but differ in the arrangement of the atoms or groups in space. Stereoisomers include enantiomers, diastereomers, conformational isomers, and the like.

[0126] As used herein, the term "enantiomers" refers to two stereoisomers of a compound that are non-superimposable mirror images of one another.

[0127] The term "diastereomer" as used herein refers to stereoisomers having two or more chiral centers and whose molecules are not mirror images of each other. Diastereomers have different physical properties, such as melting points, boiling points, spectral properties or biological activities. Mixtures of diastereomers can be separated by high resolution analytical methods such as electrophoresis and chromatography such as HPLC.

[0128] Stereochemical definitions and conventions may be followed in SP Parker, ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., "Stereochemistry of Organic Compounds", John Wiley & Sons, Inc., New York, 1994. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane polarized light. In describing optically active compounds, the prefixes D and L or R and S are used to indicate the absolute configuration of the molecule about its chiral center. The prefixes d and l or (+) and (-) are used to indicate the sign of the rotation of plane polarized light by the compound, where (-) or l indicates that the compound is left-handed. Compounds prefixed with (+) or d are right-handed. For a given chemical structure, these stereoisomers are identical except that they are mirror images of each other. Specific stereoisomers may also be referred to as enantiomers, and mixtures of such isomers are often referred to as enantiomeric mixtures. A 50:50 mixture of enantiomers is called a racemic mixture or racemate, which may occur when there is no stereoselectivity or stereospecificity in a chemical reaction or process. The terms "racemic mixture" and "racemate" refer to an equimolar mixture of two enantiomers that are optically inactive.

[0129] The racemic mixture can be used in its own form or split into individual isomers. Stereochemically pure compounds or mixtures enriched in one or more isomers can be obtained by splitting. Methods for separating isomers are well known (see Allinger NL and Eliel EL, "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971), including physical methods, such as chromatography using chiral adsorbents. Individual isomers in chiral form can be prepared from chiral precursors. Alternatively, the individual isomers can be chemically separated from the mixture by forming diastereomeric salts with chiral acids (e.g., individual enantiomers of 10-camphorsulfonic acid, camphoric acid, α-bromocamphoric acid, tartaric acid, diacetyltartaric acid, malic acid, pyrrolidone-5-carboxylic acid, etc.), fractionally crystallizing the salts, then freeing one or both of the resolved bases, and optionally repeating this process to obtain one or both isomers that are substantially free of the other isomer, i.e., the desired stereoisomers having an optical purity of, for example, at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5% by weight. Alternatively, as is well known to those skilled in the art, the racemates can be covalently linked to chiral compounds (auxiliaries) to obtain diastereomers.

[0130] The compounds of the present invention may exist in specific tautomers. Unless otherwise specified, the term "tautomer" or "tautomeric form" means that at room temperature, different functional group isomers are in dynamic equilibrium and can quickly convert to each other. If tautomers are possible (such as in solution), the chemical equilibrium of tautomers can be achieved. For example, proton tautomers (proton tautomers) (also known as prototropic tautomers) include interconversions carried out by proton migration, such as keto-enol isomerization and imine-enamine isomerization. Valence isomers (valence tautomers) include interconversions carried out by the reorganization of some bonding electrons. A specific example of keto-enol tautomerization is the interconversion between the two tautomers of pentane-2,4-dione and 4-hydroxypent-3-ene-2-one.

[0131] The compounds of the invention may contain unnatural proportions of atomic isotopes on one or more of the atoms that make up the compound. For example, the compounds may be labeled with radioactive isotopes, such as tritium ( 3 H), iodine-125( 125 I) or C-14( 14C). For another example, deuterium can be used to replace hydrogen to form a deuterated drug. The bond between deuterium and carbon is stronger than the bond between ordinary hydrogen and carbon. Compared with undeuterated drugs, deuterated drugs have the advantages of reducing toxic side effects, increasing drug stability, enhancing efficacy, and extending the biological half-life of drugs. All isotopic composition changes of the compounds of the present invention, whether radioactive or not, are included in the scope of the present invention.

[0132] "Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.

[0133] The compounds of the present invention can be prepared by a variety of synthetic methods well known to those skilled in the art, including the specific embodiments listed below, embodiments formed by combining them with other chemical synthesis methods, and equivalent substitutions well known to those skilled in the art. Preferred embodiments include but are not limited to the embodiments of the present invention.

[0134] The solvent used in the present invention is commercially available.

[0135] Compounds are named according to the conventional nomenclature in the art or using The software names were used, and commercially available compounds were named using the supplier's catalog names.

[0136] The compounds disclosed in the present invention may have one or more chiral centers, each of which independently has an R configuration or an S configuration. The chiral centers of some of the compounds disclosed in the present invention are marked with *R, *S, R*, or S*, indicating that the absolute configuration of the chiral center of the compound has not been identified, but the compound has been chirally resolved and the chiral center is a chiral center of a single configuration, the compound is a single configuration enantiomer monomer, or a single configuration diastereoisomer monomer, or a diastereoisomer mixture with a single configuration of the chiral center (for example: other chiral center configurations have not been resolved). When the absolute configuration (R configuration, or S configuration) of the chiral center of the compounds disclosed in the present invention has not been identified, such compounds can be identified according to their corresponding retention time (R configuration) under corresponding chromatographic column conditions (for example, chromatographic column model, chromatographic column filling material, chromatographic column size, mobile phase, etc.). T ) for confirmation.

[0137] The present invention is explained in more detail in the following examples. However, it should be understood that these examples are for illustrating the present invention and are not intended to limit the scope of the present invention in any way. The experimental methods in the following examples, if no specific conditions are specified, are usually based on the conventional conditions of this type of reaction, or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are weight percentages and weight parts. Unless otherwise stated, the ratio of liquid is volume ratio.

[0138] Technical and scientific terms used herein without specific definition have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. DETAILED DESCRIPTION

[0139] The present application is described in detail below by way of examples, but it is not intended that there is any adverse limitation to the present application. The present application has been described in detail herein, and its specific embodiments are also disclosed therein. It will be apparent to those skilled in the art that various changes and modifications can be made to the specific embodiments of the present application without departing from the spirit and scope of the present application.

[0140] Unless otherwise specified, the raw materials used in the present invention are commercially available.

[0141] The structures of the compounds were determined by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). NMR shifts (δ) were expressed in 10 -6 The unit of (ppm) is given. NMR measurements were performed using a Bruker ASCEND TM -400 NMR spectrometer, the solvents used for determination were deuterated sulfoxide (DMSO-d6), deuterated chloroform (CDCl3), deuterated methanol (CD3OD, the internal standard was tetramethylsilane (TMS)

[0142] MS was determined using Agilent 6110, Agilent 1100, Agilent 6120, and Agilent 6125B liquid chromatography-mass spectrometers.

[0143] HPLC determination was performed using Shimadzu HPLC-2010C high pressure liquid chromatograph (XBRIDGE 2.1*50mm, 3.5μm column)

[0144] Chiral HPLC analysis was performed using THARSFC X5.

[0145] The thin layer chromatography silica gel plate used was Yantai Qingdao GF254 silica gel plate. The silica gel plate used in thin layer chromatography (TLC) had a specification of 0.15mm-0.2mm, and the specification used for thin layer chromatography separation and purification products was 0.4mm-0.5mm.

[0146] Column chromatography generally uses Qingdao Marine Silica Gel 200-300 mesh silica gel as the carrier.

[0147] High performance liquid phase preparation used Waters2767, Waters2545, and Chuangxin Hengtong LC3000 preparative chromatographs.

[0148] Chiral preparative column chromatography used Shimadzu LC20-AP and THARSFC PREP80.

[0149] The pressurized hydrogenation reaction uses a Beijing Jiawei Kechuang Technology GCD-500G hydrogen generator.

[0150] The microwave reaction was carried out using a Biotage initiator+ type microwave reactor.

[0151] Unless otherwise specified in the experimental examples, the reactions were carried out under argon or nitrogen atmosphere.

[0152] Argon atmosphere or nitrogen atmosphere means that the reaction bottle is connected to an argon or nitrogen balloon with a capacity of about 1 liter.

[0153] Hydrogen atmosphere means that the reaction bottle is connected to a hydrogen balloon with a capacity of about 1 liter.

[0154] Unless otherwise specified in the experimental examples, the reaction temperature is room temperature, ranging from 20°C to 30°C.

[0155] Example 1: Synthesis of Compound 1

[0156]

[0157] Step 1: Preparation of compound 1-2

[0158] Water (175 mL) was added to a mixture of 1,1-dibromo-3,3,3-trifluoroacetone (73.8 g) and sodium acetate (22.6 g). The reaction system was stirred at 100°C for 1 hour and then cooled to room temperature. A solution of compound 1-1 (50.0 g, 250 mmol) in a mixed solvent of methanol (1350 mL) and ammonia (320 mL) was added to the reaction system. The reaction system was stirred at room temperature for 40 minutes and then stirred at 100°C for 2 hours. LCMS showed that the reaction was complete. The reaction solution was cooled to room temperature, quenched with water (500 mL), and extracted with ethyl acetate (500 mL×3). The combined organic phases were washed with saturated brine (100 mL×2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / ethyl acetate=2 / 1) to obtain compound 1-2 (20.0 g).

[0159] LC-MS(ESI)[M+H] + 307.0 / 309.0.

[0160] Step 2: Preparation of compound 1-3

[0161] N,N-dimethylformamide (200 mL) was added to a mixture of compound 1-2 (20.0 g), 1,2-dibromoethane (44.0 g) and cesium carbonate (85.0 g). The reaction system was stirred at 100°C for 3 hours. LCMS showed that the reaction was complete. The reaction solution was cooled to room temperature and filtered. Water (1000 mL) was added to the filtrate, and ethyl acetate (500 mL×3) was used for extraction. The combined organic phases were concentrated under reduced pressure, and the residue was purified by column chromatography (petroleum ether / ethyl acetate=3 / 1) to obtain compound 1-3 (6.00 g).

[0162] LC-MS(ESI)[M+H] + 333.0 / 335.0.

[0163] Step 3: Preparation of Compound 1-4

[0164] Methanol (20.0 mL) was added to a mixture of compound 1-3 (2.00 g), triethylamine (1.82 g) and [1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (2.46 g). The reaction system was stirred at 85°C for 48 hours under a carbon monoxide atmosphere. LCMS showed that the reaction was complete. The reaction solution was cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by column chromatography (petroleum ether / ethyl acetate = 3 / 1) to obtain compound 1-4 (1.20 g).

[0165] LC-MS(ESI)[M+H] + 312.9.

[0166] Step 4: Preparation of Compound 1-5

[0167] At 0°C, lithium aluminum tetrahydride (730 mg) was added in batches to a solution of compound 1-4 (1.20 g) in ultra-dried tetrahydrofuran (20.0 mL). Stirring was continued at this temperature for 2 hours. LCMS showed that the reaction was complete. Methanol was added dropwise to the reaction solution until no more bubbles were generated. The filtrate was filtered and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / ethyl acetate = 2 / 1) to obtain compound 1-5 (450 mg).

[0168] LC-MS(ESI)[M+H] + 285.1.

[0169] Step 5: Preparation of Compound 1-6

[0170] Dichloromethane (5.00 mL) was added to a mixture of compound 1-5 (130 mg) and manganese dioxide (200 mg). The reaction system was stirred at room temperature for 16 hours. LCMS showed that the reaction was complete. The filtrate was filtered and concentrated under reduced pressure. The obtained residue was purified by column chromatography (petroleum ether / ethyl acetate = 2 / 1) to obtain compound 1-6 (113 mg).

[0171] LC-MS(ESI)[M+H] + 282.9.

[0172] Step 6: Preparation of Compound 1-7

[0173] Water (0.5 mL) and isopropanol (0.5 mL) were added to a mixture of compound 1-6 (110 mg), 2-(4-cyclopropyl-6-methoxy-5-pyrimidinyl)pyrrolo[3,2-d]pyrimidine (104 mg) and potassium carbonate (64.0 mg). The reaction system was stirred at 70°C for 16 hours. LCMS showed that the reaction was complete. The reaction solution was cooled to room temperature, quenched with water (10 mL), and extracted with ethyl acetate (50 mL×3). The combined organic phases were concentrated under reduced pressure, and the resulting residue was purified by reverse phase column chromatography (water / acetonitrile=4 / 6) to obtain compound 1-7 (59.0 mg).

[0174] LC-MS(ESI)[M+H] + 549.9.

[0175] Step 7: Preparation of Compound 1

[0176] Under nitrogen protection and 0°C, trifluoroacetic acid (28.0 mg) and triethylsilane (28.0 mg) were added to a solution of compound 1-7 (45.0 mg) in chloroform (0.5 mL). The reaction system was stirred at room temperature for 16 hours. LCMS showed that the reaction was complete. Saturated sodium bicarbonate (10 mL) was added to quench the mixture, and ethyl acetate (30 mL×3) was used for extraction. The combined organic phases were concentrated under reduced pressure, and the resulting residue was purified by preparative HPLC (formic acid system) to obtain compound 1 (12.0 mg).

[0177] LC-MS(ESI)[M+H] + 534.2.

[0178] 1H NMR (400MHz, DMSO-d6) δ11.78(s,1H),8.99(s,1H),8.66(s,1H),8.20(d,J=8.4Hz,1H),7.92(d,J=1.2Hz,1H),7.82(d,J=2.4Hz,1H),7.09 (dd,J=8.4,1.6Hz,1H),6.97(d,J=1.6Hz,1H),4.49–4.35(m,4H),4.08(s,2H),3.82(s,3H),1.62(m,1H),1.07–0.96(m,2H),0.83(m,2H).

[0179] Example 2: Synthesis of Compound 2

[0180]

[0181] Step 1: Preparation of compound 2-2

[0182] Water (198 mL) was added to a mixture of 1,1-dibromo-3,3,3-trifluoroacetone (111 g) and sodium acetate (34.0 g). The reaction system was stirred at 100 ° C for 1 hour and then cooled to room temperature. A solution of compound 2-1 (100 g) in a mixed solvent of methanol (1950 mL) and ammonia (458 mL) was added to the reaction system. The reaction system was stirred at room temperature for 40 minutes and then stirred at 100 ° C for 2 hours. LCMS showed that the reaction was complete. The reaction solution was cooled to room temperature, quenched with water (500 mL), and extracted with ethyl acetate (500 mL × 3). The combined organic phases were washed with saturated brine (100 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / ethyl acetate = 3 / 1) to obtain compound 2-2 (90.0 g). LC-MS (ESI) [M+H] + 349.1 / 351.1.

[0183] Step 2: Preparation of compound 2-3

[0184] N,N-dimethylformamide (1800 mL) was added to a mixture of compound 2-2 (180 g), allyl iodide (95.3 g) and potassium carbonate (183 g). The reaction system was stirred at room temperature for 12 hours. LCMS showed that the reaction was complete. Water (1500 mL) was added to quench the mixture, and ethyl acetate (500 mL×3) was used for extraction. The combined organic phases were concentrated under reduced pressure, and the obtained residue was purified by column chromatography (petroleum ether / ethyl acetate=4 / 1) to obtain compound 2-3 (130 g).

[0185] LC-MS(ESI)[M+H] + 389.1 / 391.1.

[0186] Step 3: Preparation of compound 2-4

[0187] At room temperature, compound 2-3 (130 g), potassium vinyl trifluoroborate (112 g) and potassium carbonate (92.3 g) were dissolved in a mixed solvent (1,4-dioxane / water = 1000 / 300 mL). Catalyst [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (24.4 g) was added to replace argon. The reaction mixture was stirred at 100°C for 12 hours. LCMS showed that the reaction was complete. Cooled to room temperature, diluted with water (1000 mL), and extracted with ethyl acetate (500 mL×3). The combined organic phases were washed with water (500 mL) and saturated sodium chloride solution (500 mL) in turn, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (petroleum ether / ethyl acetate = 4 / 1) to obtain compound 2-4 (80.0 g).

[0188] LC-MS(ESI)[M+H] + 337.3.

[0189] Step 4: Preparation of compound 2-5

[0190] Add dichloromethane (800 mL) to a mixture of compound 2-4 (80.0 g) and Grubbs 2nd generation catalyst (20.2 g). The reaction system was stirred at room temperature for 5 hours. LCMS showed that the reaction was complete. Dilute with water (800 mL), dichloromethane (500 mL × 3). The combined organic phases were washed with water (500 mL) and saturated sodium chloride solution (500 mL) in turn, dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was separated and purified by column chromatography (petroleum ether / ethyl acetate = 4 / 1) to obtain compound 2-5 (34.0 g).

[0191] LC-MS(ESI)[M+H] + 309.3.

[0192] Step 5: Preparation of Compound 2-6

[0193] At 0°C, a cyclohexane solution of diisobutylaluminum hydride (1.00 mol / L, 551 mL, 551 mmol) was added dropwise to a solution of compound 2-5 (34.0 g) in ultra-dry tetrahydrofuran (340 mL). The reaction system was stirred at room temperature for 5 hours. LCMS showed that the reaction was complete. Saturated aqueous ammonium chloride solution (100 mL) was added to quench. Filtered, the filtrate was extracted with ethyl acetate (300 mL × 3). The combined organic phases were washed with saturated brine (200 mL × 2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / ethyl acetate = 3 / 1) to obtain compound 2-6 (21.0 g).

[0194] LC-MS(ESI)[M+H] + 283.3.

[0195] Step 6: Preparation of Compound 2-7

[0196] At 0°C, dichloromethane (80.0 mL) was added to a mixture of compound 2-6 (8.00 g) and manganese dioxide (49.0 g). The reaction system was stirred at temperature for 4 hours. LCMS showed that the reaction was complete. The filtrate was filtered and concentrated under reduced pressure. The residue was purified by column chromatography (petroleum ether / ethyl acetate = 3 / 1) to obtain compound 2-7 (4.64 g).

[0197] LC-MS(ESI)[M+H] + 281.2.

[0198] Step 7: Preparation of Compound 2-8

[0199] Water (35 mL) and isopropanol (35 mL) were added to a mixture of compound 2-7 (3.50 g), 2-(4-cyclopropyl-6-methoxy-5-pyrimidinyl)pyrrolo[3,2-d]pyrimidine (3.50 g) and potassium carbonate (6.00 g). The reaction system was stirred at 70°C for 16 hours. LCMS showed that the reaction was complete. The reaction solution was cooled to room temperature, quenched with water (100 mL), and extracted with ethyl acetate (100 mL×3). The combined organic phases were concentrated under reduced pressure, and the resulting residue was purified by reverse phase column chromatography (water / acetonitrile=4 / 6) to obtain compound 2-8 (1.10 g).

[0200] LC-MS(ESI)[M+H] + 548.0.

[0201] Step 8: Preparation of Compound 2

[0202] Under nitrogen protection and 0°C, trifluoroacetic acid (4.00 mL) and triethylsilane (4.00 mL) were added to a solution of compound 2-8 (1.00 g) in chloroform (20 mL). The reaction system was stirred at room temperature for 16 hours. LCMS showed that the reaction was complete. Saturated sodium bicarbonate (20 mL) was added to quench the mixture, and the mixture was extracted with ethyl acetate (80 mL × 3). The combined organic phases were concentrated under reduced pressure, and the resulting residue was purified by preparative HPLC (ammonia system) to give compound 2 (400 mg).

[0203] LC-MS(ESI)[M+H] + 532.0.

[0204] 1 H NMR(400MHz,DMSO-d6)δ11.82(s,1H),9.01(s,1H),8.66(s,1H),7.94(s,1H ),7.84(s,1H),7.56(d,J=7.8Hz,1H),7.36–7.27(m,2H),4.14(s,2H),3.96( t,J=6.7Hz,2H),3.82(s,3H),2.61(t,J=6.9Hz,2H),2.28–2.15(m,2H),1.58 (dt,J=12.6,4.1Hz,1H),1.02(d,J=3.8Hz,2H),0.81(dd,J=7.9,3.1Hz,2H).

[0205] Example 3: Synthesis of Compound 3

[0206]

[0207] Step 1: Preparation of compound 3

[0208] Compound 2 (120 mg), cesium carbonate (225 mg), and 2,2,2-trifluoroethyl trifluoromethanesulfonate (160 mg) were added to N,N-dimethylformamide (1.2 mL), and the reaction solution was stirred at room temperature for 16 hours. The reaction solution was filtered and liquid phase was used to prepare compound 3 (94.88 mg).

[0209] LC-MS(ESI)[M+H] + 614.1.

[0210] 1H NMR (400MHz, DMSO-d6) δ9.27(s,1H),8.68(s,1H),8.23(s,0.1H),7.95(d,J=1.1Hz,1 H),7.83(s,1H),7.58(d,J=7.6Hz,1H),7.32(dd,J=12.0,4.4Hz,2H),5.40(q,J=9.2H z,2H),4.15(s,2H),3.96(t,J=6.8Hz,2H),3.83(s,3H),2.62(t,J=7.2Hz,2H),2.22( t,J=6.8Hz,2H),1.66–1.48(m,1H),1.04(dd,J=7.2,4.0Hz,2H),0.871–0.78(m,2H).

[0211] Example 4: Synthesis of Compound 4

[0212]

[0213] Step 1: Preparation of compound 4

[0214] Compound 1 (60 mg), cesium carbonate (71 mg), and 2,2,2-trifluoroethyl trifluoromethanesulfonate (51 mg) were added to N,N-dimethylformamide (1.5 mL), and the reaction solution was stirred at room temperature for 16 hours. The reaction solution was filtered and liquid phase was used to prepare compound 4 (10.90 mg).

[0215] LC-MS(ESI)[M+H] + 616.0.

[0216] 1 H NMR (400MHz, DMSO-d6) δ9.26(s,1H),8.68(s,1H),8.50(s,0.52H),8.22(d,J=8.0Hz,1H),7.93(s,1H),7.84(s,1H),7.10(d,J=8.4Hz,1H) ,6.98(s,1H),5.39(q,J=9.2Hz,2H),4.43(s,4H),4.10(s,2H),3.83(s,3H),1.63–1.53(m,1H),1.03(s,2H),0.84(dd,J=8.0,3.2Hz,2H).

[0217] Example 5: Synthesis of Compound 5

[0218]

[0219] Step 1: Preparation of compound 5-1

[0220] Compound 2-6 (4 g) was added to tetrahydrofuran (60 mL), and the temperature was lowered to 0°C under nitrogen protection. Phosphorus tribromide (11.51 g) was added dropwise to the reaction solution. After the reaction solution was stirred at room temperature for 1 hour, aqueous sodium bicarbonate solution was added to the reaction solution to quench it. The solution was extracted with ethyl acetate three times, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and the filtrate was concentrated and purified by column chromatography (petroleum ether / ethyl acetate = 7 / 3) to obtain compound 5-1 (2 g).

[0221] LC-MS (ESI) [M+3H] + 346.8.

[0222] Step 2: Preparation of compound 5-2

[0223] Compound 5-1 (2 g), bis-pinacol borate (2.19 g), potassium acetate (1.70 g) and ditriphenylphosphine palladium dichloride (0.40 g) were dissolved in dioxane (20 mL). Under nitrogen protection, the reaction solution was stirred at 100 ° C for 12 hours. The reaction solution was filtered, water was added to the organic phase, and extracted with ethyl acetate. The organic phase was concentrated to obtain a crude product, which was then subjected to column chromatography (petroleum ether / ethyl acetate = 5 / 1) to obtain compound 5-2 (1.9 g). LC-MS (ESI) [M+H] + 393.0.

[0224] Step 3: Preparation of compound 5-3

[0225] 1H-pyrazolo[4,3-d]pyrimidine and 3-bromo-5-(4-cyclopropyl-6-methoxy-5-pyrimidinyl)-1-[[2-(trimethylsilyl)ethoxy]methyl] (70.00 mg), 1,1'-bis(diphenylphosphino)ferrocene[1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (32.93 mg) and potassium phosphate (79.60 mg) were added to 1,4-dioxane (1.5 mL), followed by water (0.3 mL), nitrogen was replaced, the temperature was raised to 110° C., and a solution of 1,4-dioxane (0.5 mL) containing compound 5-2 (88.25 mg) was added dropwise to the reaction system, and then stirred at 110° C. for 1 hour. The reaction was substantially complete as detected by LCMS. Ice water was added to quench the reaction, and ethyl acetate (30 mL) was used for extraction three times. The organic phases were combined, dried over anhydrous sodium sulfate, and the concentrated residue was purified by column chromatography (petroleum ether / ethyl acetate = 3 / 1) to give compound 5-3 (20.0 mg).

[0226] LC-MS(ESI)[M+H] + 663.2.

[0227] Step 4: Preparation of compound 5

[0228] Compound 5-3 (20.00 mg) was dissolved in dichloromethane (1.0 mL), nitrogen was replaced, and trifluoroacetic acid (1.0 mL) was slowly added dropwise after cooling to 0°C in an ice-water bath. The reaction system was heated to room temperature and stirred for 2 hours. The reaction solution was then concentrated, tetrahydrofuran (1.0 mL) was added, ammonia water (1.0 mL) was slowly added dropwise, and stirred at room temperature for 1 hour. LCMS showed that the reaction was complete, and water was directly added to quench the reaction. The system was acidified with dilute hydrochloric acid, extracted three times with ethyl acetate (20 mL), the organic phases were combined, dried over anhydrous sodium sulfate, and the concentrated residue was purified by liquid phase preparation (FA acid method) to obtain compound 5 (2.91 mg).

[0229] LC-MS(ESI)[M+H] + 533.3.

[0230] 1 H NMR (400MHz, CDCl3-d) δ9.20 (s, 1H), 8.66 (s, 1H), 7.96 (d, J = 6.3Hz, 1H), 7.43 (m, 3H), 4.52 (s, 2 H),3.98(m,2H),3.88(s,3H),2.73(s,2H),2.39(s,2H),1.57(m,1H),1.18(m,2H),0.78(m,2H).

[0231] Example 6: Synthesis of Compound 6

[0232]

[0233] Step 1: Preparation of compound 6-1

[0234] Compound 1-5 (1.35 g) was added to tetrahydrofuran (10 mL), and the temperature was lowered to 0°C under nitrogen protection. Phosphorus tribromide (2.57 g) was added dropwise to the reaction solution. After the reaction solution was stirred at room temperature for 1 hour, aqueous sodium bicarbonate solution was added to the reaction solution to quench it. The mixture was extracted with ethyl acetate three times, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, and the filtrate was concentrated and purified by column chromatography (petroleum ether / ethyl acetate = 7 / 3) to obtain compound 6-1 (500 mg).

[0235] LC-MS (ESI) [M+3H] + 348.9.

[0236] Step 2: Preparation of compound 6-2

[0237] Compound 6-1 (0.5 g), bis-pinacol borate (0.77 g), potassium acetate (0.42 g) and ditriphenylphosphine palladium dichloride (0.20 g) were added to dioxane (5 mL). The reaction solution was stirred at 100 ° C for 12 hours under nitrogen protection. The reaction solution was filtered, water was added to the organic phase, and extracted with ethyl acetate. The organic phase was concentrated to obtain a crude product, which was then purified by column chromatography (petroleum ether / ethyl acetate = 5 / 1) to obtain compound 6-2 (0.3 g). LC-MS (ESI) [M+H] + 395.0.

[0238] Step 3: Preparation of compound 6-3

[0239] Compound 6-2 (165 mg), 1H-pyrazolo[4,3-d]pyrimidine and 3-bromo-5-(4-cyclopropyl-6-methoxy-5-pyrimidinyl)-1-[[2-(trimethylsilyl)ethoxy]methyl] (200 mg), 1,1'-bis(diphenylphosphino)ferrocene[1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (92 mg) and potassium phosphate (223 mg) were added to a mixed solvent of toluene (3.0 mL) and water (0.3 mL), and the mixture was subjected to microwave reaction at 100° C. for 1 hour under argon protection. Aqueous solution (10 mL) was added, and the mixture was extracted twice with ethyl acetate (10 mL), the organic phases were combined, dried over anhydrous sodium sulfate, and the concentrated residue was purified by column chromatography (petroleum ether / ethyl acetate=1 / 1) to obtain compound 6-3 (80 mg).

[0240] LC-MS(ESI)[M+H] + 665.2.

[0241] Step 4: Preparation of compound 6

[0242] Compound 6-3 (80.00 mg) was dissolved in anhydrous dichloromethane (1.0 mL) and protected by nitrogen. After the reaction system was cooled to 0 ° C, trifluoroacetic acid (1.0 mL) was slowly added dropwise, and the reaction system was heated to room temperature and stirred for 2 hours. Then, anhydrous tetrahydrofuran (1.0 mL) was added after the reaction solution was concentrated, and ammonia (1.0 mL) was slowly added dropwise, and stirred at room temperature for 30 minutes. Water (10 mL) was added to quench the reaction, and ethyl acetate (10 mL) was used for extraction twice. The organic phases were combined, dried over anhydrous sodium sulfate, and the concentrated residue was prepared by liquid phase to obtain compound 6 (21.24 mg).

[0243] LC-MS(ESI)[M+H] + 534.9.

[0244] 1H NMR (400MHz, DMSO-d6) δ9.42(s,1H),8.69(s,1H),8.22(d,J=8.3Hz,1H),7.93(s,1H),7.12(dd,J=8.3,1.4Hz ,1H),7.02(s,1H),4.46–4.39(m,4H),4.37(s,2H),3.84(s,3H),1.67–1.56(m,1H),1.05(m,2H),0.85(m,2H).

[0245] Example 7: Synthesis of Compound 7

[0246]

[0247] Step 1: Preparation of compound 7-2

[0248] Compound 7-1 (1.76 g) was dissolved in anhydrous N, N-dimethylformamide (20.0 mL) solvent, and after the reaction system was cooled to 0°C, N, N-diisopropylethylamine (3.93 g) and 2, 2, 2-trifluoroethyl trifluoromethanesulfonate (4.71 g) were added in sequence, and then the mixture was heated to room temperature and stirred for 1 hour. LCMS showed that the reaction was complete. Ice water was added to quench, and the mixture was extracted three times with ethyl acetate (50 mL). The organic phases were combined and washed three times with saturated brine, dried over anhydrous sodium sulfate, and the concentrated residue was purified by column chromatography (dichloromethane / methanol = 95 / 5) to obtain compound 7-2 (1.9 g).

[0249] LC-MS(ESI)[M+H] + 428.9.

[0250] Step 2: Preparation of compound 7

[0251] Compound 7-2 (257 mg), compound 5-1 (200 mg), pinacol diboron (321 mg), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (47 mg), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (28 mg) and potassium phosphate (382 mg) were added to a mixture of 1,4-dioxane (4 mL) and water (0.4 mL). The reaction solution was stirred at 100°C for 16 hours. Water was added to the reaction solution, extracted with ethyl acetate, and the organic phase was concentrated and liquid phase was used to prepare compound 7 (2.25 mg).

[0252] LC-MS(ESI)[M+H] + 615.2.

[0253] 1H NMR (400MHz, DMSO-d6) δ9.67(s,1H),8.71(s,1H),7.95(s,1H),7.59(d,J=8.0Hz,1H),7.42–7.31(m,2H),5.67(d,J=8.8Hz,2H),4.4 4(s,2H),3.96(t,J=6.8Hz,2H),3.83(s,3H),2.62(t,J=7.2Hz,2H),2.28–2.16(m,2H),1.58(s,1H),1.05(s,2H),0.86–0.78(m,2H).

[0254] Example 8: Synthesis of Compound 8

[0255]

[0256] Step 1: Preparation of compound 8

[0257] Compound 7-2 (257 mg), compound 6-1 (200 mg), pinacol diboron (321 mg), chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (47 mg), 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (28 mg) and potassium phosphate (382 mg) were added to a mixture of 1,4-dioxane (4 mL) and water (0.4 mL). The reaction solution was stirred at 100° C. for 16 hours. Water was added to the reaction solution, extracted with ethyl acetate, and the organic phase was concentrated and liquid phase was used to prepare compound 8 (3.59 mg).

[0258] LC-MS(ESI)[M+H] + 617.1.

[0259] 1 H NMR (400MHz, DMSO-d6) δ9.67(s,1H),8.71(s,1H),8.23(d,J=8.4Hz,1H),7.94(s,1H),7.12(d,J=8.4Hz,1H),7.01(s,1H),5.6 6(q,J=8.8Hz,2H),4.41(d,J=13.2Hz,6H),3.84(s,3H),1.66–1.57(m,1H),1.06(d,J=3.2Hz,2H),0.86(dd,J=7.6,3.2Hz,2H).

[0260] Example 9: Synthesis of Compound 9

[0261]

[0262] Step 1: Preparation of compound 9-1

[0263] Compound 7-1 (500.00 mg) was dissolved in N, N-dimethylformamide (10.0 mL), cooled to 0°C in an ice-water bath, cesium carbonate (938.36 mg) and iodoethane (449.19 mg) were added, and stirred at room temperature for 1 hour. After the reaction was detected by LCMS, an aqueous solution of ammonium chloride (10 mL) was added to quench the reaction, and the mixture was extracted three times with ethyl acetate (20 mL), the organic phases were combined, washed three times with saturated brine, dried over anhydrous sodium sulfate, and the concentrated residue was slurried with ethyl acetate (5 mL), filtered, and the filter cake was taken and dried under reduced pressure to obtain compound 9-1 (150.0 mg).

[0264] LCMS(ESI)[M+H] + 377.1.

[0265] Step 2: Preparation of compound 9

[0266] Compound 9-1 (100.00 mg), compound 5-2 (158.85 mg), 1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (39.51 mg) and potassium phosphate (143.28 mg) were added to 1,4-dioxane (2.0 mL), followed by water (0.4 mL), nitrogen was replaced, microwave heating was performed to 110 ° C and stirred for 2 hours. LCMS detected that the reaction was basically complete. Ice water was added to quench the reaction, ethyl acetate (20 mL) was extracted three times, the organic phases were combined, dried over anhydrous sodium sulfate, and the concentrated residue was purified by preparative purification (FA acid method) to obtain compound 9 (29.76 mg).

[0267] LCMS(ESI)[M+H] + 561.4.

[0268] 1 H NMR (400MHz, DMSO-d6) δ9.60 (s, 1H), 8.70 (s, 1H), 7.95 (d, J = 1.0Hz, 1H), 7. 58(d,J=7.8Hz,1H),7.39–7.33(m,2H),4.62–4.57(m,2H),4.41(s,2H),3.96 (t,J=6.7Hz,2H),3.83(s,3H),2.62(t,J=7.0Hz,2H),2.25–2.18(m,2H),1.6 2–1.55(m,1H),1.50(t,J=7.2Hz,3H),1.08–1.01(m,2H),0.85–0.80(m,2H).

[0269] Example 10: Synthesis of Compound 10

[0270]

[0271] Step 1: Preparation of compound 10-1

[0272] Compound 7-1 (400.00 mg) was dissolved in N, N-dimethylformamide (8.0 mL), cooled to 0°C in an ice-water bath, cesium carbonate (749.39 mg) and iodomethane (326.46 mg) were added, and stirred at room temperature for 1 hour. After the reaction was completed by LCMS detection, an aqueous solution of ammonium chloride (10 mL) was added to quench the reaction, and the mixture was extracted three times with ethyl acetate (20 mL), the organic phases were combined, washed three times with saturated brine, dried over anhydrous sodium sulfate, and the concentrated residue was slurried with ethyl acetate (5 mL), filtered, and the filter cake was taken and dried under reduced pressure to obtain compound 10-1 (230.0 mg).

[0273] LCMS(ESI)[M+H] + 361.1.

[0274] Step 2: Preparation of compound 10

[0275] Compound 10-1 (100.00 mg), compound 5-2 (164.73 mg), 1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (40.98 mg) and potassium phosphate (148.59 mg) were added to 1,4-dioxane (3.0 mL), followed by water (0.3 mL), nitrogen was replaced, and the mixture was heated to 110 ° C and stirred for 16 hours. LCMS detected that the reaction was basically complete. Ice water was added to quench the reaction, and the mixture was extracted three times with ethyl acetate (20 mL), the organic phases were combined, dried over anhydrous sodium sulfate, and the concentrated residue was purified by preparative purification (FA acid method) to obtain compound 10 (26.47 mg).

[0276] LCMS(ESI)[M+H] + 547.4.

[0277] 1 H NMR (400MHz, DMSO-d6) δ9.55(s,1H),8.70(s,1H),7.95(d,J=1.0Hz,1H),7.58(d,J=7.8Hz,1H),7.38–7.32(m,2H),4.40(s,2H),4.20(s,3 H),3.95(t,J=6.7Hz,2H),3.83(s,3H),2.62(t,J=7.0Hz,2H),2.25–2.18(m,2H),1.61–1.53(m,1H),1.08–1.02(m,2H),0.85–0.80(m,2H).

[0278] Example 11: Synthesis of Compound 11

[0279]

[0280] Step 1: Preparation of compound 11-1

[0281] Compound 7-1 (500.00 mg) was dissolved in N, N-dimethylformamide (10.0 mL), cooled to 0°C in an ice-water bath, cesium carbonate (938.36 mg) and isopropyl iodide (489.57 mg) were added, and stirred at room temperature for 1 hour. After the reaction was detected by LCMS, an aqueous solution of ammonium chloride (10 mL) was added to quench the reaction, and the mixture was extracted three times with ethyl acetate (20 mL), the organic phases were combined, washed three times with saturated brine, dried over anhydrous sodium sulfate, and the concentrated residue was slurried (ethyl acetate / petroleum ether=1 / 4), filtered, and the filter cake was dried under reduced pressure to obtain compound 11-1 (200.0 mg).

[0282] LCMS(ESI)[M+H] + 391.1.

[0283] Step 2: Preparation of compound 11

[0284] Compound 11-1 (100.00 mg), compound 5-2 (110 mg), 1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (37.51 mg) and potassium phosphate (110 mg) were added to 1,4-dioxane (1 mL), followed by water (0.1 mL), nitrogen was replaced, and the mixture was heated to 100 ° C and stirred for 16 hours. LCMS detected that the reaction was basically complete. Ice water was added to quench the reaction, and ethyl acetate (20 mL) was extracted three times. The organic phases were combined, dried over anhydrous sodium sulfate, and the concentrated residue was purified by preparative purification (FA acid method) to obtain the final product 11 (6.40 mg).

[0285] LCMS(ESI)[M+H] + 575.4.

[0286] 1H NMR (400 MHz, CD3OD) δ9.47 (s, 1H), 8.64 (s, 1H), 7.72 (d, J = 1.1 Hz, 1H), 7.55 (d, J = 7.9 Hz, 1H), 7.41 (d, J = 7.8 Hz, 2H), 5.21-5.08 (m, 1H), 4.48 (s, 2H), 3.96 (t, J = 6.8 Hz, 2H), 3.90 (s, 3H), 2.67 (t, J = 7.1 Hz, 2H), 2.32 (t, J = 7.0 Hz, 2H), 1.64 (t, J = 8.2 Hz, 7H), 1.14 (dd, J = 4.6, 2.9 Hz, 2H), 0.86 (dd, J = 8.1, 2.9 Hz, 2H). Example 12: Synthesis of Compound 12a and Compound 12b

[0287]

[0288] Step 1: Preparation of compound 12-2

[0289] Compound 12-1 (40 g), 3-butyn-2-ol (12.05 g), and triphenylphosphine (90.16 g) were added to tetrahydrofuran (400 mL). Under N2 protection, diisopropyl azodicarboxylate (69.51 g, 43.74 mmol) was added dropwise to the reaction solution at 0°C. The reaction solution was reacted at room temperature for 16 hours. Water was added to the reaction solution, extracted with ethyl acetate three times, washed with saturated sodium chloride aqueous solution, and the organic phase was concentrated and purified by normal phase column (ethyl acetate: petroleum ether = 1 / 5) to obtain compound 12-2 (32 g).

[0290] LC-MS(ESI)[M+H] + 403.0.

[0291] Step 2: Preparation of compound 12-3

[0292] Compound 12-2 (34 g) was added to a tetrahydrofuran solution of 9-borabicyclo[3.3.1]nonane (dimer) (0.5 M), and the reaction solution was reacted at 70° C. for 1.5 hours under N2 protection. Water was added to the reaction solution, and it was extracted with ethyl acetate (500 mL*3). The organic phase was concentrated and passed through a normal phase column (methanol: dichloromethane = 0-10%) to obtain compound 12-3 (21.4 g).

[0293] LC-MS (ESI) [M+3H] + 449.0.

[0294] Step 3: Preparation of compound 12-4

[0295] Compound 12-3 (11 g), potassium phosphate (15.67 g), tetrakistriphenylphosphine palladium (2.84 g) were added to 1,4-dioxane (300 mL) and water (30 mL), and the reaction solution was stirred at 80°C for 16 hours under nitrogen protection. Water was added to the reaction solution, extracted with ethyl acetate, and the organic phase was concentrated and passed through a normal phase column (ethyl acetate: petroleum ether = 1 / 5) to obtain compound 12-4 (4 g).

[0296] LC-MS (ESI) [M+3H] + 325.1.

[0297] Step 4: Preparation of compound 12-5

[0298] Compound 12-4 (3.9 g) was dissolved in tetrahydrofuran (39 mL), and lithium aluminum tetrahydride solution (15.64 mL, 1 M, 15.64 mmol) was added to the reaction solution at 0°C. The reaction was stirred at 0°C for 1 hour. The reaction solution was slowly poured into ice water, extracted with ethyl acetate, and the organic phase was concentrated to obtain compound 12-5 (2 g).

[0299] LC-MS(ESI)[M+H] + 297.2.

[0300] Step 5: Preparation of compound 12-6

[0301] At room temperature, phosphorus tribromide (8.23 g) was slowly added dropwise to a tetrahydrofuran solution of 12-5 (3 g), and the reaction solution was stirred at room temperature for 2 h. The reaction solution was slowly poured into an icy sodium carbonate aqueous solution, extracted with ethyl acetate, and the organic phase was concentrated to obtain 12-6 (2.86 g).

[0302] LC-MS (ESI) [M+2H] + 361.0.

[0303] Step 6: Preparation of compound 12-7

[0304] Compound 12-6 (3 g), bipyraclostrobin (3.18 g), potassium acetate (2.46 g), and bis(triphenylphosphine)palladium dichloride (1.17 g) were added to 1,4-dioxane (30 mL), and the reaction solution was stirred at 100° C. for 16 hours. The reaction solution was spin-dried and passed through a normal phase column (ethyl acetate: petroleum ether = 10%) to obtain the target compound 12-7 (2 g).

[0305] LC-MS (ESI) [M+2H] + 407.1.

[0306] Step 7: Preparation of compound 12-8

[0307] Compound 12-7 (471 mg), compound 7-2 (500 mg), potassium phosphate (738 mg), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium (169 mg) were added to toluene (5 mL) and water (0.5 mL), and the reaction solution was stirred at 120° C. for 16 h. Water was added to the reaction solution, extracted with ethyl acetate, and the organic phase was concentrated and then chiral separation and preparation were performed to obtain the target compound 12-8.

[0308] Step 8: Preparation of compounds 12a and 12b

[0309] Compound 12-8 was prepared by chiral SFC (column OJ (250*25mm, 10μm); mobile phase [A: carbon dioxide, B: methanol (containing 0.1% diethylamine)]; B%: 15% to 15%) to obtain compound 12a (retention time 0.781 minutes) (53.34 mg), and compound 12b (retention time 1.287 minutes) (46.13 mg). The retention time was determined by the following analytical method: Column: DAICEL IB100*3.0mm, 3μm, mobile phase [Α: carbon dioxide, B: methanol (containing 0.1% diethylamine)], 40% B, flow rate: 1.5mL / min, column temperature: 35℃.

[0310] Compound 12a:

[0311] LC-MS(ESI)[M+H] + 629.2.

[0312] 1 H NMR (400MHz, DMSO-d6) δ9.68(s,1H),8.71(s,1H),7.94(d,J=1.2Hz,1H),7.57(d,J=7.6Hz ,1H),7.42–7.30(m,2H),5.67(q,J=9.0Hz,2H),4.44(s,2H),4.07–3.94(m,1H),3.83(s,3 H),2.76–2.61(m,1H),2.45(dd,J=14.0,6.8Hz,1H),2.35–2.22(m,1H),2.10–1.92(m,1H) ,1.66–1.53(m,1H),1.44(d,J=6.8Hz,3H),1.13–0.97(m,2H),0.83(dd,J=8.0,3.2Hz,2H).

[0313] Compound 12b:

[0314] LC-MS(ESI)[M+H] + 629.2.

[0315] 1 H NMR (400MHz, DMSO-d6) δ9.68(s,1H),8.71(s,1H),7.94(d,J=1.1Hz,1H),7.57(d,J=7.6Hz ,1H),7.42–7.30(m,2H),5.67(q,J=9.0Hz,2H),4.44(s,2H),4.07–3.94(m,1H),3.83(s,3 H),2.76–2.61(m,1H),2.45(dd,J=14.0,6.8Hz,1H),2.35–2.22(m,1H),2.10–1.92(m,1H) ,1.66–1.53(m,1H),1.44(d,J=6.8Hz,3H),1.13–0.97(m,2H),0.83(dd,J=8.0,3.2Hz,2H).

[0316] Example 13: Synthesis of Compound 13a and Compound 13b

[0317]

[0318] Step 1: Preparation of compound 13-2

[0319] Compound 13-1 (1.50 g) and pyridine (2.1 g) were dissolved in anhydrous dichloromethane (15.0 mL) solvent, nitrogen protection, cooled to 0 ° C, trifluoromethanesulfonic anhydride (3.71 g) was added dropwise, and then naturally warmed to room temperature and stirred for 1 hour. After the reaction solution was allowed to stand, the supernatant was directly used in the next step. Compound 7-1 (800 mg) was dissolved in N, N-dimethylformamide (10.0 mL) solvent, cesium carbonate (2248 mg) was added, and then the above supernatant was added dropwise, and the reaction was stirred at room temperature overnight. The dichloromethane was removed by concentration under reduced pressure, water (30 mL) was added, and ethyl acetate (50 mL) was used to extract twice, the organic phases were combined, washed three times with saturated brine (50 mL), dried over anhydrous sodium sulfate, and the concentrated residue was purified by column chromatography (petroleum ether / ethyl acetate = 100% / 0% to 70% / 30%) to obtain compound 13-2 (600 mg).

[0320] LCMS(ESI)[M+H] + 443.0.

[0321] Step 2: Preparation of compound 13-3

[0322] Compound 13-2 (300 mg), compound 5-2 (267 mg), toluene (3.0 mL) and water (0.3 mL) were added to a microwave tube, followed by potassium phosphate (289 mg) and 1,1'-bis(diphenylphosphino)ferrocene]palladium dichloride (149 mg), nitrogen was replaced, and the reaction was stirred at 110°C for 2 hours. The reaction system was cooled to room temperature, pad with diatomaceous earth and anhydrous sodium sulfate, filtered, and the filter cake was rinsed with ethyl acetate (100 mL). The filtrate was taken and the concentrated residue was purified by column chromatography (petroleum ether / ethyl acetate = 100% / 0% to 85% / 15%) to obtain compound 13-3 (130 mg).

[0323] Step 3: Preparation of compounds 13a and 13b

[0324] Compound 13-3 (130 mg) was subjected to chiral preparative SFC (column OJ (250*25mm, 10μm); mobile phase [A: carbon dioxide, B: methanol (containing 0.1% diethylamine)]; B%: 30% to 30%) to obtain compound 13a (retention time 0.781 minutes) (31.11 mg, yield 7.31%) and compound 13b (retention time 3.098 minutes) (25.82 mg, yield 6.07%). The retention time was determined by the following analytical method: Column: OJ 100*3.0mm, 3μm, mobile phase [Α: carbon dioxide, B: methanol (containing 0.1% diethylamine)], 20% B, flow rate: 1.5mL / min, column temperature: 35℃.

[0325] Compound 13a:

[0326] LC-MS(ESI)[M+H] + 629.2.

[0327] 1 H NMR(400MHz,DMSO-d6)δ9.73(s,1H),8.71(s,1H),7.95(s,1H),7.59(d,J=7.9 Hz,1H),7.39(s,1H),7.35(d,J=7.9Hz,1H),6.24–5.96(m,1H),4.45(s,2H),3 .96(t,J=6.6Hz,2H),3.83(s,3H),2.62(t,J=6.9Hz,2H),2.25–2.20(m,2H),1 .88(d,J=6.9Hz,3H),1.63–1.53(m,1H),1.06–1.04(m,2H),0.84–0.81(m,2H).

[0328] Compound 13b:

[0329] LC-MS(ESI)[M+H] + 629.2.

[0330] 1 H NMR(400MHz,DMSO-d6)δ9.73(s,1H),8.71(s,1H),7.95(s,1H),7.59(d,J=7.9 Hz,1H),7.39(s,1H),7.35(d,J=8.0Hz,1H),6.21–6.01(m,1H),4.45(s,2H),3 .96(t,J=6.6Hz,2H),3.83(s,3H),2.62(t,J=6.8Hz,2H),2.28–2.16(m,2H),1 .88(d,J=6.9Hz,3H),1.59–1.55(m,1H),1.05–1.02(m,2H),0.84–0.81(m,2H).

[0331] Comparative Example

[0332] The preparation method of the reference compound is described in the reference (Compound 54, page 232 of WO2022174184A1).

[0333]

[0334] Biological Examples

[0335] Test Example 1: USP1 / UAF1 deubiquitination assay (Ubiquitin Fluorophore Assay)

[0336] 1. Prepare USP1 / UAF1 complex: First, prepare reaction buffer (50 mM HEPES [pH 7.8], 0.5 mM EDTA, 1 mM DTT, 0.1 mg / ml BSA and 0.01% Tween-20), and use the reaction buffer to prepare a final concentration of 0.15 nM USP1 / UAF1 complex (R&D, E-568-050) enzyme mixture.

[0337] 2. Prepare Ubiquitin Rhodamine 110 reaction substrate: Use reaction buffer (50 mM HEPES [pH 7.8], 0.5 mM EDTA, 1 mM DTT, 0.1 mg / ml BSA and 0.01% Tween-20) to prepare a substrate mixture with a final concentration of 150 nM Ubiquitin Rhodamine 110 (R&D, E-555-050).

[0338] 3. Compound preparation: The test compound is dissolved in DMSO, and the final concentration of DMSO is 1%. The compound is prepared with DMSO to different concentrations, and duplicate wells are set for each concentration, with 3-fold gradient dilution, a total of 11 concentrations, and corresponding solvent controls are set at the same time. After dilution, the compound is diluted 25 times with reaction buffer.

[0339] 4. USP1 / UAF1 deubiquitination reaction: Add 5uL 4x USP1 / UAF1 complex solution and 5uL 4x compound to each well of the test plate and incubate for 15 minutes, then add 10uL 2x Ubiquitin Rhodamine 110 reaction substrate to start the reaction. Centrifuge, seal the plate, and incubate at 37°C for 30 minutes.

[0340] 5. After the reaction, the fluorescence value was read using a microplate reader (MD, VersaMax), with an excitation wavelength of 480 nm and an emission wavelength of 540 nm. Finally, the data were analyzed using GraphPad Prism 8 software, and the IC was calculated using the dose-response-inhibition (four-parameter) equation using GraphPad Prism software. 50 value.

[0341] The experimental results are shown in Table 1.

[0342] Table 1: IC values ​​of selected compounds in USP1 / UAF1 deubiquitination assay 50 value

[0343]

[0344]

[0345] As shown in the experimental results in Table 1, the compounds of the present invention have excellent in vitro activity and can inhibit the deubiquitinating activity of USP1 / UAF1 on Ubiquitin Rhodamine 110.

[0346] Test Example 2: MDA-MB-436 BRCA1Mut Cell Proliferation Inhibition Assay (MDA-MB-436 BRCA1 MutCTG Assay)

[0347] 1. Prepare DMEM cell culture medium: First, prepare DMEM cell culture medium (10% FBS, 1% Pen Strep, 10 μg / ml Insulin).

[0348] 2. Prepare MDA-MB-436BRCA1Mut cells: Take out MDA-MB-436 cells from the liquid nitrogen tank, revive the cells with DMEM medium and culture them to the logarithmic growth phase. When the cell confluence reaches more than 80%, collect the cells, plate 3000 cells per well, 80ul volume, and culture overnight at 37℃, 5% CO2.

[0349] 3. Compound preparation: Dissolve the test compound in DMSO to prepare a 10mM stock solution. Dilute the stock solution 20 times with cell culture medium, then dilute 3 times to different concentrations, set duplicate wells for each concentration, a total of 9 concentrations, and set corresponding solvent controls. After dilution, dilute the compound 100 times with DMEM culture medium.

[0350] 4. Drug treatment: Add 20ul of compound working solution to each well of the cell culture plate, set up a positive control and a cell-free negative control, and continue to culture for 10 days. The final concentration of DMSO in the system is 0.01%.

[0351] 5.CTG test: according to Prepare CTG detection reagent according to the Luminescent Cell Viability Assay instructions, add 50ul CTG detection reagent to each well of the cell culture plate, incubate in the dark for 15 minutes, and then read the plate.

[0352] 6. Use an ELISA reader (MD, VersaMax) to read the luminescent signal. Finally, use GraphPad Prism 8 software to analyze the data, and use the dose-response-inhibition (four-parameter) equation to calculate the IC through GraphPad Prism software 50 value.

[0353] The experimental results are shown in Table 2.

[0354] Table 2. IC of selected compounds in the MDA-MB-436BRCA1Mut cell proliferation inhibition assay 50 value

[0355]

[0356]

[0357] As shown in the experimental results in Table 2, the compounds of the present invention have excellent in vitro activity and can inhibit the cell proliferation process of human breast cancer cells MDA-MB-436BRCA1Mut.

[0358] Test Example 3: Pharmacokinetic Test

[0359] 1. Purpose of the experiment

[0360] ICR mice were used as test animals, and Example 1, the comparative example and KSQ-4279 were administered orally. The drug concentrations in plasma at different times were determined by LC-MS / MS to study the pharmacokinetic characteristics of the compounds of the present invention and the comparative example compounds in mice.

[0361] 2. Experimental plan

[0362] 2.1 Experimental drugs and animals

[0363] Experimental drugs: Example 1, comparative example and KSQ-4279;

[0364] Animals: ICR mice, male, 20-30 g, purchased from Shanghai Jihui Biotechnology Co., Ltd.

[0365] 2.2 Drug preparation

[0366] Weigh an appropriate amount of Example 1, add an appropriate amount of 5% DMSO + 10% Solutol + 85% Saline, vortex and ultrasonically prepare a 1 mg / mL clear solution. Weigh an appropriate amount of Comparative Example, add an appropriate amount of 5% DMSO + 10% Solutol + 85% Saline, vortex and ultrasonically prepare a 1 mg / mL clear solution. Weigh an appropriate amount of KSQ-4279, add an appropriate amount of 5% DMSO + 10% Solutol + 85% Saline, vortex and ultrasonically prepare a 1 mg / mL clear solution.

[0367] 2.3 Administration

[0368] ICR mice in the intravenous and oral gavage groups (3 mice in each group) of each test compound were fasted overnight and then gavaged (IV, 1 mg / kg, 5 mL / kg; PO, 10 mg / kg, 10 mL / kg), and were fed 4 hours after the administration.

[0369] 3. Operation

[0370] Before administration and at 0.083 hours, 0.25 hours, 0.5 hours, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours and 24 hours after administration, approximately 0.03 mL of blood was collected through the eye socket and anticoagulated with sodium heparin. After blood sample collection, place on ice and centrifuge to separate plasma (centrifugation conditions:

[0371] 1500 g, 10 min). The collected plasma was stored at -60 to -80°C before analysis.

[0372] The content of the test compound in mouse plasma after intravenous and oral administration was determined by LC-MS / MS.

[0373] 4. Pharmacokinetic parameter results

[0374] The pharmacokinetic parameters of Example 1 of the present invention and the comparative example are shown in Table 3.

[0375] Table 3 Pharmacokinetic results in mice

[0376]

[0377]

[0378] Conclusion: Compared with the comparative example and KSQ-4279, the blood drug concentration and the area under the curve of Example 1 were significantly improved, showing good pharmacokinetic characteristics in animals.

[0379] Test Example 4: Pharmacokinetic Test

[0380] 1. Experimental purpose:

[0381] ICR mice were used as test animals, and Example 2 and KSQ-4279 were administered by gavage. The drug concentrations in plasma at different times were determined by LC-MS / MS to study the pharmacokinetic characteristics of the compound of the present invention and the Yangshen compound KSQ-4279 in mice.

[0382] 2. Experimental plan:

[0383] Experimental drugs and animals:

[0384] Experimental drugs: Example 2 and KSQ-4279;

[0385] Experimental animals: 3 SPF ICR mice, 6-8 weeks old, weighing 22 g;

[0386] Solvent: 5% DMSO+10% solutol+85% saline;

[0387] Preparation: The dosing solution was prepared on the day of administration. Weigh 9.5 mg of the compound and dissolve it in an appropriate amount of DMSO to prepare a stock solution with a concentration of 200.0 mg / mL. Pipette 0.042 ml of the stock solution, add 0.084 ml of solutol, ultrasonicate for 2 min, vortex for 2 min, then add 0.714 ml of saline, vortex for 2 min, and ultrasonicate for 2 min to obtain a 10.0 mg / mL colorless, clear, pH=7 oral dosing solution for animals in the 100 mpk dose group.

[0388] Administration: Take 3 healthy male SPF-grade ICR mice, 6-8 weeks old, weighing 22g. After 3 days of adaptive feeding, the mice were fasted overnight (10-12h) the night before the experiment, and 10mg / mL of the dosing solution was administered according to the dosing volume of 10ml / kg. Drinking water freely during the experiment, and eating was resumed 4h after administration. Timing began after oral administration, and blood was collected at the planned time points before and after administration (0.083, 0.25, 0.5, 1, 2, 4, 6, 8, 10, 24, 48h), and 50μL of whole blood was collected at each point into a 1.5mL EP tube containing sodium heparin (placed on ice). The collected whole blood was placed on a vortex instrument and shaken twice to mix, placed on wet ice, centrifuged at 8000rpm for 5min at 4℃ within 1h, and the supernatant plasma was stored in a -80℃ refrigerator until processed and analyzed.

[0389] 3. Pharmacokinetic parameter results

[0390] The comparison of pharmacokinetic parameters between Example 2 of the present invention and Yangshen KSQ-4279 is shown in Table 4.

[0391] Table 4 Pharmacokinetic results in mice

[0392]

[0393] Conclusion: Compared with KSQ-4279, Example 2 showed a significant increase in the blood drug concentration and area under the curve in mice at a high dose of 100 mpk, showing good pharmacokinetic characteristics in animals.

[0394] The exemplary embodiments of the present invention are described above. It should be understood that the protection scope of the present application is not limited to the above exemplary embodiments. Any modification, equivalent substitution, improvement, etc. made by those skilled in the art within the spirit and principle of the present invention shall be included in the protection scope of the present application.

Claims

1. A compound represented by formula (I), an optical isomer thereof or a pharmaceutically acceptable salt thereof, in, X1 is selected from N and CR 1X ; X2 is selected from N and CR 2X ; X3 Selected from NR 3X ; X4 selected from N and CR 4X ; R1, R 1X , R 2X , R 3X , R 4X Each independently selected from H, OH, NH2, NRxR Y 、CN、F、Cl、Br、I、C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl and -OC 3-6 Cycloalkyl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl or -OC 3-6 Cycloalkyl is optionally substituted with 1, 2 or 3 OH, NH2, F, Cl, Br, I, CN, NO2, COOH; R2 is selected from phenyl, naphthyl and 5-6 membered heteroaryl, wherein the phenyl, naphthyl or 5-6 membered heteroaryl is optionally substituted with 1, 2, 3, 4 or 5 R'; R', Rx, R Y Each independently selected from H, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Heteroalkyl, -S(=O)2C 1-6 Alkyl, -OC 3-9 Cycloalkyl, -O-3-9 membered heterocyclic group, C 3-9 Cycloalkyl and 3-9 membered heterocyclic group, the C 1-6 Alkyl, C 1-6 Heteroalkyl, -S(=O)2C 1-6 Alkyl, -OC 3-9 Cycloalkyl, -O-3-9 membered heterocyclic group, C 3-9 Cycloalkyl or 3-9 membered heterocyclic group is optionally substituted by 1, 2 or 3 D, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 1-6 Alkylamino substitution; L is selected from CR3R4, NR3, O, S, S(=O) and S(=O)2; R3 and R4 are each independently selected from H, OH, CN, F, Cl, Br, I, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl and C 3-6 Cycloalkyl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl or C 3-6 Cycloalkyl is optionally substituted with 1, 2 or 3 OH, NH2, F, Cl, Br, I, CN, NO2, COOH; Or, R3, R4 together with the carbon atom to which they are attached form C 3-6 Cycloalkyl, 3-9 membered heterocyclic group, C 6-14 Aryl or 5-6 membered heteroaryl, the C 3-6 Cycloalkyl, 3-9 membered heterocyclic group, C 6-14 The aryl or 5-6 membered heteroaryl is optionally substituted with 1, 2 or 3 OH, NH2, halogen, CN, C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl or -OC 3-6 Cycloalkyl substitution; X5, X6, X7, T1, T2 are each independently selected from N and CR 5X ; R 5X Selected from H, OH, CN, F, Cl, Br, I, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl and C 3-6 Cycloalkyl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl or C 3-6 Cycloalkyl is optionally substituted with 1, 2 or 3 OH, NH2, F, Cl, Br, I, CN, NO2, COOH; J, K, and M are each independently selected from CR 6A R 6B NR 6A , O, S, S(=O), S(=O)(=NH) and S(=O)2; R 6A , R 6B Each independently selected from H, OH, CN, F, Cl, Br, I, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl and C 3-6 Cycloalkyl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl or C 3-6 Cycloalkyl is optionally substituted with 1, 2 or 3 OH, NH2, F, Cl, Br, I, CN, NO2, COOH; Ring A is selected from C 3-9 Cycloalkyl, C 6-14 Aryl, 5-9 membered heteroaryl, 3-9 membered heterocyclic group, the C 3-9 Cycloalkyl, C 6-14 Aryl, 5-9 membered heteroaryl, 3-9 membered heterocyclyl are optionally substituted by 1, 2 or 3 R5; R5 is selected from H, D, CN, F, Cl, Br, I, -C(=O)R a 、-C(=O)OR b 、-NR a R b 、-NR a C(=O)R b 、-NR a C(=O)NR a R b 、-S(O)2NR a R b 、-C(=O)NR a R b 、-S(O)2R a 、-NR a S(O)2R b , -C 1-6 Alkyl-C(=O)NR a R b , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl, C 3-9 Cycloalkyl, OC 3-9 Cycloalkyl, C 6-14 Aryl, 5-9 membered heteroaryl, 3-9 membered heterocyclic group, -O-3-9 membered heterocyclic group, -OC 6-14 Aryl and -O-5-9 membered heteroaryl, the -C(=O)R a 、-C(=O)OR b 、-NR a R b 、-NR a C(=O)R b 、-NR a C(=O)NR a R b 、-S(O)2NR a R b 、-C(=O)NR a R b 、-S(O)2R a 、-NR a S(O)2R b , -C 1-6 Alkyl-C(=O)NR a R b , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl, C 3-9 Cycloalkyl, OC 3-9 Cycloalkyl, C 6-14 Aryl, 5-9 membered heteroaryl, 3-9 membered heterocyclic group, -O-3-9 membered heterocyclic group, -OC 6-14 Aryl or -O-5-9 membered heteroaryl is optionally substituted with 1, 2 or 3 D, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 1-6 Alkylamino substitution; Or, two optional R5 on ring A together with the carbon atom to which they are attached form C 3-6 Cycloalkyl, 3-9 membered heterocyclic group, C 6-14 Aryl or 5-6 membered heteroaryl, the C 3-6 Cycloalkyl, 3-9 membered heterocyclic group, C 6-14 The aryl or 5-6 membered heteroaryl is optionally substituted with 1, 2 or 3 OH, NH2, halogen, CN, C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl or -OC 3-6 Cycloalkyl substitution; R a , R b Each independently selected from H, D, CN, F, Cl, Br, I, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl, C 3-9 Cycloalkyl, OC 3-9 Cycloalkyl, C 6-14 Aryl, 5-9 membered heteroaryl, 3-9 membered heterocyclic group, -O-3-9 membered heterocyclic group, -OC 6-14 Aryl and -O-5-9 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl, C 3-9 Cycloalkyl, OC 3-9 Cycloalkyl, C 6-14 Aryl, 5-9 membered heteroaryl, 3-9 membered heterocyclic group, -O-3-9 membered heterocyclic group, -OC 6-14 Aryl and -O-5-9 membered heteroaryl are optionally substituted with 1, 2 or 3 OH, NH2, halogen, CN, C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl or -OC 3-6 Cycloalkyl substitution; The C 1-6 The heteroalkyl, 3-9 membered heterocyclyl, 5-9 membered heterocyclyl, 5-6 membered heterocyclyl, 5-9 membered heteroaryl, 5-6 membered heteroaryl contain 1, 2, 3 or 4 heteroatoms or heteroatom groups independently selected from -O-, -NH-, -N=, -S-, -C(=O)-, -C(=O)O-, -S(=O)-, -S(=O)2- and N.

2. The compound according to claim 1, its optical isomer or a pharmaceutically acceptable salt thereof, whose structure is shown below, in, Y1, Y2, Y3, Y4, Y5 are each independently selected from N or C(R'); R' is independently selected from H, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Heteroalkyl, -S(=O)2C 1-6 Alkyl, -OC 3-9 Cycloalkyl, -O-3-9 membered heterocyclic group, C 3-9 Cycloalkyl and 3-9 membered heterocyclic group, the C 1-6 Alkyl, C 1-6 Heteroalkyl, -S(=O)2C 1-6 Alkyl, -OC 3-9 Cycloalkyl, -O-3-9 membered heterocyclic group, C 3-9 Cycloalkyl or 3-9 membered heterocyclic group is optionally substituted by 1, 2 or 3 D, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 1-6 Alkylamino substituted.

3. The compound according to claim 1, its optical isomer or a pharmaceutically acceptable salt thereof, whose structure is shown below, in, R 2A , R 2B , R 2C , R 2D , R 2E , R 2F , R 2G , R 2H , R 2I , R 2J , R 2K , R 2L , R 2M , R 2N , R 2O Each independently selected from H, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Heteroalkyl, -S(=O)2C 1-6 Alkyl, -OC 3-9 Cycloalkyl, -O-3-9 membered heterocyclic group, C 3-9 Cycloalkyl and 3-9 membered heterocyclic group, the C 1-6 Alkyl, C 1-6 Heteroalkyl, -S(=O)2C 1-6 Alkyl, -OC 3-9 Cycloalkyl, -O-3-9 membered heterocyclic group, C 3-9 Cycloalkyl or 3-9 membered heterocyclic group is optionally substituted by 1, 2 or 3 D, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 1-6 Alkylamino substituted.

4. The compound according to claim 1, its optical isomer or a pharmaceutically acceptable salt thereof, whose structure is shown below, in, R 5A , R 5B , R 5C , R 5D , R 5E , R 5F , R 5G , R 5H , R 5I Each independently selected from H, D, CN, F, Cl, Br, I, -C(=O)R a 、-C(=O)OR b 、-NR a R b 、-NR a C(=O)R b 、-NR a C(=O)NR a R b 、-S(O)2NR a R b 、-C(=O)NR a R b 、-S(O)2R a 、-NR a S(O)2R b , -C 1-6 Alkyl-C(=O)NR a R b , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl, C 3-9 Cycloalkyl, OC 3-9 Cycloalkyl, C 6-14 Aryl, 5-9 membered heteroaryl, 3-9 membered heterocyclic group, -O-3-9 membered heterocyclic group, -OC 6-14 Aryl and -O-5-9 membered heteroaryl, the -C(=O)R a 、-C(=O)OR b 、-NR a R b 、-NR a C(=O)R b 、-NR a C(=O)NR a R b 、-S(O)2NR a R b 、-C(=O)NR a R b 、-S(O)2R a 、-NR a S(O)2R b , -C 1-6 Alkyl-C(=O)NR a R b , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl, C 3-9 Cycloalkyl, OC 3-9 Cycloalkyl, C 6-14 Aryl, 5-9 membered heteroaryl, 3-9 membered heterocyclic group, -O-3-9 membered heterocyclic group, -OC 6-14 Aryl or -O-5-9 membered heteroaryl is optionally substituted with 1, 2 or 3 D, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 1-6 Alkylamino substitution; R a , R b Each independently selected from H, D, CN, F, Cl, Br, I, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl, C 3-9 Cycloalkyl, OC 3-9 Cycloalkyl, C 6-14 Aryl, 5-9 membered heteroaryl, 3-9 membered heterocyclic group, -3-9 membered heterocyclic group, -OC 6-14 Aryl and -O-5-9 membered heteroaryl, the C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Heteroalkyl, C 3-9 Cycloalkyl, OC 3-9 Cycloalkyl, C 6-14 Aryl, 5-9 membered heteroaryl, 3-9 membered heterocyclic group, -O-3-9 membered heterocyclic group, -OC 6-14 Aryl and -O-5-9 membered heteroaryl are optionally substituted with 1, 2 or 3 OH, NH2, halogen, CN, C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl or -OC 3-6 Cycloalkyl substitution.

5. The compound according to any one of claims 1 to 4, its optical isomer or a pharmaceutically acceptable salt thereof, wherein: Structural unit Selected from Optionally, the structural unit Selected from 6. The compound according to claim 1 or 5, its optical isomer or a pharmaceutically acceptable salt thereof, wherein: R1, R 1X , R 2X , R 3X , R 3Y , R 4X Each independently selected from H, OH, NH2, NRxR Y 、CN、F、Cl、Br、I、C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, C 2-3 Alkenyl, C 2-3 Alkynyl, C 3-6 Cycloalkyl and -OC 3-6 Cycloalkyl, the C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, C 2-3 Alkenyl, C 2-3 Alkynyl, C 3-6 Cycloalkyl or -OC 3-6 Cycloalkyl is optionally substituted with 1, 2 or 3 OH, NH2, F, Cl, Br, I, CN, NO2, COOH; Optionally, R1, R 1X , R 2X , R 3X , R 3Y , R 4X Each independently selected from H, OH, NH2, NRxR Y , CN, F, Cl, Br, I, methyl, ethyl and propyl; Rx, R Y Each independently selected from H, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Heteroalkyl, -S(=O)2C 1-6 Alkyl, -OC 3-9 Cycloalkyl, -O-3-9 membered heterocyclic group, C 3-9 Cycloalkyl and 3-9 membered heterocyclic group, the C 1-6 Alkyl, C 1-6 Heteroalkyl, -S(=O)2C 1-6 Alkyl, -OC 3-9 Cycloalkyl, -O-3-9 membered heterocyclic group, C 3-9 Cycloalkyl or 3-9 membered heterocyclic group is optionally substituted by 1, 2 or 3 D, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 1-6 Alkylamino substituted.

7. The compound according to claim 1 or 4, its optical isomer or a pharmaceutically acceptable salt thereof, wherein: R2 is selected from phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrrolyl and pyrazolyl, wherein the phenyl, naphthyl, pyridinyl, pyrimidinyl, pyrrolyl or pyrazolyl is optionally substituted with 1, 2, 3 or 4 R'; Optionally, R' is each independently selected from H, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, -S(=O)2C 1-3 Alkyl, -OC 3-6 Cycloalkyl, -O-3-6 membered heterocyclic group, C 3-6 Cycloalkyl and 3-6 membered heterocyclic group, the C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, -S(=O)2C 1-3 Alkyl, -OC 3-6 Cycloalkyl, -O-3-6 membered heterocyclic group, C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups are optionally substituted by 1, 2 or 3 D, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio or C 1-3 Alkylamino substitution; Optionally, R' is each independently selected from H, CN, methyl, ethyl, -OCH3, -OCH2CH3, -OCD3, -OCHF2, -SCH3, Optionally, R2 is selected from R 2A , R 2B , R 2C , R 2D , R 2E , R 2F , R 2G , R 2H , R 2I , R 2J , R 2K , R 2L , R 2M , R 2N , R 2O Selected from H, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Heteroalkyl, -S(=O)2C 1-6 Alkyl, -OC 3-9 Cycloalkyl, -O-3-9 membered heterocyclic group, C 3-9 Cycloalkyl and 3-9 membered heterocyclic group, the C 1-6 Alkyl, C 1-6 Heteroalkyl, -S(=O)2C 1-6 Alkyl, -OC 3-9 Cycloalkyl, -O-3-9 membered heterocyclic group, C 3-9 Cycloalkyl or 3-9 membered heterocyclic group is optionally substituted by 1, 2 or 3 D, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 1-6 Alkylamino substitution; Optionally, R2 is selected from 8. The compound according to claim 3 or 7, its optical isomer or a pharmaceutically acceptable salt thereof, wherein: R 2A , R 2B , R 2C , R 2D , R 2E , R 2F , R 2G , R 2H , R 2I , R 2J , R 2K , R 2L , R 2M , R 2N , R 2O Each independently selected from H, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, -S(=O)2C 1-3 Alkyl, -OC 3-6 Cycloalkyl, -O-3-6 membered heterocyclic group, C 3-6 Cycloalkyl and 3-6 membered heterocyclic group, the C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, -S(=O)2C 1-3 Alkyl, -OC 3-6 Cycloalkyl, -O-3-6 membered heterocyclic group, C 3-6 Cycloalkyl and 3-6 membered heterocyclic groups are optionally substituted by 1, 2 or 3 D, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio or C 1-3 Alkylamino substitution; Optionally, R 2A , R 2B , R 2C , R 2D , R 2E , R 2F , R 2G , R 2H , R 2I , R 2J , R 2K , R 2L , R 2M , R 2N , R 2O Each independently selected from H, CN, methyl, ethyl, -OCH3, -OCH2CH3, -OCD3, -OCHF2, -SCH3, 9. The compound according to any one of claims 1 to 4, its optical isomer or a pharmaceutically acceptable salt thereof, wherein: L is selected from CR3R4, R3 and R4 are each independently selected from H, OH, CN, F, Cl, Br, I, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, C 2-3 Alkenyl, C 2-3 Alkynyl and C 3-6 Cycloalkyl, the C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, C 2-3 Alkenyl, C 2-3 Alkynyl or C 3-6 Cycloalkyl is optionally substituted with 1, 2 or 3 OH, NH2, F, Cl, Br, I, CN, NO2 or COOH; Optionally, R3, R4 are each independently selected from H, D, OH, CN, F, Cl, Br, I, methyl, ethyl and propyl.

10. The compound according to claim 1, 2 or 3, its optical isomer or a pharmaceutically acceptable salt thereof, wherein: Structural unit Selected from R 5A , R 5B , R 5C , R 5D , R 5E , R 5F , R 5G , R 5H , R 5I Each independently selected from H, D, CN, F, Cl, Br, I, C 1-6 Alkyl, C 1-6 Heteroalkyl, -OC 3-6 Cycloalkyl, -O-3-6 membered heterocyclic group, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group and -C 1-6 Alkyl-C(=O)N(C 1-6 Alkyl)2, the C 1-6 Alkyl, C 1-6 Heteroalkyl, -OC 3-6 Cycloalkyl, -O-3-6 membered heterocyclic group, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group or -C 1-6 Alkyl-C(=O)N(C 1-6 The alkyl)2 is optionally substituted with 1, 2 or 3 D, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 1-6 Alkylamino substitution; Optionally, R 5A , R 5B , R 5C , R 5D , R 5E , R 5F , R 5G , R 5H , R 5I Each independently selected from H, D, CN, F, Cl, Br, I, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, -OC 3-6 Cycloalkyl, -O-3-6 membered heterocyclic group, C 3-6 Cycloalkyl, 3-6 membered heteroalkyl and -C 1-3 Alkyl-C(=O)N(C 1-3 Alkyl)2, the C 1-3 Alkylthio, C 1-3 Alkylamino, -OC 3-6 Cycloalkyl, -O-3-6 membered heterocyclic group, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group or -C 1-3 Alkyl-C(=O)N(C 1-3 The alkyl)2 is optionally substituted with 1, 2 or 3 D, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 1-6 Alkylamino substitution; Optionally, R 5A , R 5B , R 5C , R 5D , R 5E , R 5F , R 5G , R 5H , R 5I Each independently selected from H, D, CN, F, Cl, Br, I, OCH3, OCH2CH3, CF3, CHF2, CD3, methyl, ethyl, Optionally, Selected from 11. The compound according to claim 1, 2 or 3, its optical isomer or a pharmaceutically acceptable salt thereof, wherein: J, K, and M are each independently selected from CR 6A R 6B and O; R 6A , R 6B Each independently selected from H, OH, CN, F, Cl, Br, I, C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, C 2-3 Alkenyl, C 2-3 Alkynyl and C 3-6 Cycloalkyl, the C 1-3 Alkyl, C 1-3 Alkoxy, C 1-3 Alkylthio, C 1-3 Alkylamino, C 2-3 Alkenyl, C 2-3 Alkynyl or C 3-6 Cycloalkyl is optionally substituted with 1, 2 or 3 OH, NH2, F, Cl, Br, I, CN, NO2 or COOH; Optionally, R 6A , R 6B Each is independently selected from H, D, OH, CN, F, Cl, Br, I, methyl, ethyl and propyl.

12. The compound according to claim 1, 2, 3 or 11, its optical isomer or a pharmaceutically acceptable salt thereof, wherein: Structural unit Selected from R 5A , R 5B Each independently selected from H, D, CN, F, Cl, Br, I, C 1-6 Alkyl, C 1-6 Heteroalkyl, -OC 3-6 Cycloalkyl, -O-3-6 membered heterocyclic group, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group and -C 1-6 Alkyl-C(=O)N(C 1-6 Alkyl)2, the C 1-6 Alkyl, C 1-6 Heteroalkyl, -OC 3-6 Cycloalkyl, -O-3-6 membered heterocyclic group, C 3-6 Cycloalkyl, 3-6 membered heterocyclic group or -C 1-6 Alkyl-C(=O)N(C 1-6 The alkyl)2 is optionally substituted with 1, 2 or 3 D, OH, CN, F, Cl, Br, I, CN, NO2, COOH, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 1-6 Alkylamino substitution; Optionally, the structural unit Selected from 13. A compound of the following formula, an optical isomer thereof or a pharmaceutically acceptable salt thereof, which is selected from:

14. A compound of the following formula, an optical isomer thereof or a pharmaceutically acceptable salt thereof, which is selected from:

15. Use of the compound according to any one of claims 1 to 14, its optical isomer or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a disease associated with USP1 activity or expression. 16 . The disease associated with USP1 activity or expression according to claim 15 , which is selected from cancer-related diseases.

17. The cancer-related disease according to claim 16, which is selected from bone cancer, brain cancer, soft tissue cancer, kidney cancer, bladder cancer, skin cancer, lung cancer, colon cancer, nervous system cancer, head and neck cancer, pancreatic cancer, ovarian cancer, breast cancer, uterine cancer, cervical cancer.

18. The cancer-related disease according to claim 16, which is selected from osteosarcoma, chondrosarcoma, glioma, glioblastoma, astrocytoma, medulloblastoma, meningioma, rhabdoid sarcoma, melanoma, and non-small cell lung cancer.